var title_f9_57_10128="Mast cell skin";
var content_f9_57_10128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Skin mast cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mast cells may be round to spindle-shaped with eccentrically positioned unilobed nuclei. Mast cells contain numerous large granules containing proteases. The granules of mast cells in the skin predominantly contain tryptase and chymase (TC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mariana Castells, MD PhD, Lawrence B Schwartz, MD, and Shirley Craig, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10128=[""].join("\n");
var outline_f9_57_10128=null;
var title_f9_57_10129="M mode MV annular calcification";
var content_f9_57_10129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of mitral annular calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this patient mitral annular calcification (MAC) is seen in association with aortic valve stenosis. An M-mode tracing (panel A) of the aortic root (Ao) shows a thickened aortic valve (AV). Panel B shows a dense band of echoes from the mitral annulus, due to MAC, which are located posterior to the anterior leaflet of the mitral valve (ALMV); the posterior mitral valve leaflet is not seen because it is obscured by the artifacts that arise from the highly reflective, calcified annulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10129=[""].join("\n");
var outline_f9_57_10129=null;
var title_f9_57_10130="Patient information: Removing objects stuck in the ear (The Basics)";
var content_f9_57_10130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83253\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\">",
"         Normal ear",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/2/15394\">",
"         Patient information: Outer ear infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/38/1634\">",
"         Patient information: Removing objects stuck up the nose (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/45/36561\">",
"         Patient information: Ruptured eardrum (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/12/26816\">",
"         Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Removing objects stuck in the ear (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/removing-objects-stuck-in-the-ear-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13207674\">",
"      <span class=\"h1\">",
"       What kinds of objects commonly get stuck in the ear?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different things can get stuck in the ear. Children sometimes put small toys, objects, or food in their ears. Bugs can also crawl into the ear and get stuck.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207689\">",
"      <span class=\"h1\">",
"       Does an object stuck in the ear cause symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. Some children who have an object stuck in their ear have no symptoms. Other children have symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain inside the ear",
"       </li>",
"       <li>",
"        Blood or fluid leaking from the ear",
"       </li>",
"       <li>",
"        Trouble hearing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207704\">",
"      <span class=\"h1\">",
"       Should I remove an object stuck in my child&rsquo;s ear on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Do not try to grab or pull out an object that is stuck in your child&rsquo;s ear. If you do, you might push the object deeper into the ear canal (",
"      <a class=\"graphic graphic_figure graphicRef55121 \" href=\"UTD.htm?29/61/30677\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207719\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help my child on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can try to make the object fall out by itself. Have your child tilt his or her head so that the ear with the object in it is facing the ground. Then gently pull on your child&rsquo;s outer ear. This sometimes loosens the object so it falls out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207734\">",
"      <span class=\"h1\">",
"       Should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Call the doctor or nurse right away.",
"     </p>",
"     <p>",
"      If the object doesn&rsquo;t fall out on its own, the doctor or nurse will need to remove it. Depending on the object and other factors, the doctor or nurse might be able to remove the object in the office. If not, he or she will have you go to the emergency room or to an ear, nose, and throat doctor to have it removed. Batteries (such as button or disc batteries) in the ear are an emergency and need to be removed right away. That&rsquo;s because the acid in the battery can damage the inside of the ear.",
"     </p>",
"     <p>",
"      Even if the object falls out of the ear by itself, your child will still need to see the doctor or nurse. He or she will do an exam and check that no other objects are in your child&rsquo;s ears or nose. (Children sometimes put objects in their nose, too.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207749\">",
"      <span class=\"h1\">",
"       How will the doctor or nurse remove the object?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, the doctor or nurse will use a special light to look inside the ear to see the object. Depending on the object and where it is, he or she can remove it either by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Squirting water into your child&rsquo;s ear to flush the object out",
"       </li>",
"       <li>",
"        Using a tool to remove the object",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a bug is stuck in your child&rsquo;s ear and the bug is alive, the doctor will kill the bug before removing it. He or she can kill the bug by putting medicine or fluid in the ear.",
"     </p>",
"     <p>",
"      Before the doctor removes an object from your child&rsquo;s ear, he or she might give your child medicine to make him or her relaxed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207764\">",
"      <span class=\"h1\">",
"       Will my child need any other treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. An object stuck in the ear sometimes hurts the skin in the ear canal or causes an infection of the ear canal (called an outer ear infection). If these things happen, the doctor will probably prescribe ear drops that go in your child&rsquo;s ear.",
"     </p>",
"     <p>",
"      If your child has an outer ear infection, he or she should keep the inside of the ear dry while the infection heals. Your child should not swim for 7 to 10 days after starting treatment. But he or she can take a shower. To keep the ear dry during a shower, put some petroleum jelly (Vaseline&reg;) on a cotton ball, and then put the cotton ball in your child&rsquo;s ear.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207779\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/38/1634?source=see_link\">",
"       Patient information: Removing objects stuck up the nose (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=see_link\">",
"       Patient information: Outer ear infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=see_link\">",
"       Patient information: Ruptured eardrum (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=see_link\">",
"       Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/57/10130?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83253 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10130=[""].join("\n");
var outline_f9_57_10130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207674\">",
"      What kinds of objects commonly get stuck in the ear?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207689\">",
"      Does an object stuck in the ear cause symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207704\">",
"      Should I remove an object stuck in my child&rsquo;s ear on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207719\">",
"      Is there anything I can do to help my child on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207734\">",
"      Should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207749\">",
"      How will the doctor or nurse remove the object?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207764\">",
"      Will my child need any other treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207779\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\">",
"      Normal ear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=related_link\">",
"      Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=related_link\">",
"      Patient information: Outer ear infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/38/1634?source=related_link\">",
"      Patient information: Removing objects stuck up the nose (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=related_link\">",
"      Patient information: Ruptured eardrum (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_57_10131="Naphazoline (nasal): Pediatric drug information";
var content_f9_57_10131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naphazoline (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/53/29523?source=see_link\">",
"    see \"Naphazoline (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/52/40772?source=see_link\">",
"    see \"Naphazoline (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15511986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning on Accidental Ingestion of Imidazoline Derivative Eye Drops and Nasal Sprays",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) has issued a warning that accidental ingestion by children of over-the-counter (OTC) imidazoline derivative eye drops and nasal sprays may result in serious harm. The eye drops and nasal sprays involved in cases of accidental ingestion contain the imidazoline derivatives tetrahydrozoline, oxymetazoline, or naphazoline. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization were reported in children &le;5 years who had ingested even small amounts (eg, 1-2 mL). These products should be stored out of reach of children at all times; parents and caregivers should note that not all products are packaged in child-resistant packaging. If a child accidentally ingests these products, parents and caregivers should contact a poison control center at 1-800-222-1222 and seek emergency medical care immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, please refer to:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9348230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Privine&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Decongestant, Nasal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nasal Agent, Vasoconstrictor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/53/29523?source=see_link\">",
"      see \"Naphazoline (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal not recommended for use in children &lt;6 years of age (especially in infants) due to CNS depression; therapy should not exceed 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-12 years: 0.05%, 1 drop or spray every 6 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;12 years to Adults: 0.05%, 1-2 drops or sprays every 3-6 hours if needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9348351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Privine&reg;: 0.05% (25 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Privine&reg;: 0.05% (20 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Spray or drop medication into one nostril while gently occluding the other; then reverse procedure",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporarily relieves nasal congestion associated with rhinitis, sinusitis, hay fever, or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15801078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9348276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Transient stinging, nasal mucosa irritation, dryness, rebound congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Sneezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naphazoline or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rebound congestion may occur with extended use (use no longer than 3-5 days); use with caution in the presence of hypertension, diabetes mellitus, hyperthyroidism, heart disease, coronary artery disease, cerebral arteriosclerosis, or long-standing asthma",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9348279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10512509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Decongestion occurs within 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 2-6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16026 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10131=[""].join("\n");
var outline_f9_57_10131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15511986\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348230\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512501\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512511\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348351\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512512\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512503\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15801078\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348276\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512504\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512505\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299741\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348279\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512508\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512509\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/53/29523?source=related_link\">",
"      Naphazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/52/40772?source=related_link\">",
"      Naphazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/60/15300?source=related_link\">",
"      Naphazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/47/19188?source=related_link\">",
"      Naphazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/60/27587?source=related_link\">",
"      Naphazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_57_10132="Phoropter";
var content_f9_57_10132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Phoropter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A phoropter is an instrument containing different lenses used to bring the focus onto the retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10132=[""].join("\n");
var outline_f9_57_10132=null;
var title_f9_57_10133="Issues relating to the renal allograft recipient undergoing non-transplant surgery";
var content_f9_57_10133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Issues relating to the renal allograft recipient undergoing non-transplant surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10133/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10133/contributors\">",
"     Ron Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10133/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10133/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10133/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10133/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/57/10133/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As both the short- and long-term outcomes after solid organ transplantation continue to improve, an increasing number of recipients require medical care not specifically related to their transplanted organ. Some require elective or emergency surgery.",
"   </p>",
"   <p>",
"    Many of the principles of peri- and intraoperative management are the same in transplant and non-transplant patients. However, there are a few important differences. It is strongly recommended that the transplant center be consulted prior to any planned surgical intervention in kidney transplant recipients.",
"   </p>",
"   <p>",
"    Some of the general issues concerning non-transplant surgery in the transplant patient will be discussed here, as well as a few specific surgical problems. General discussions of the pre- and perioperative medical management of patients are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must integrate information from the history, physical examination, and laboratory tests to develop an initial estimate of perioperative risk. One major issue is the possible presence of significant coronary artery disease among those undergoing non-cardiac surgery, a common finding among renal transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=see_link\">",
"     \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of clinical and surgical determinants have been identified that allow cardiac risk stratification. The evaluation of patients with known or suspected cardiac disease prior to noncardiac surgery requires an appraisal of the patient's clinical risk profile in the context of the surgery to be performed and the attendant risks. Discussions of such an evaluation as well as the general preoperative evaluation of patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;When transplant recipients principally relied upon azathioprine-based immunosuppression regimens, chronic doses of corticosteroids were relatively high, with characteristic side effects observed in many transplant recipients. Adrenal suppression related to the higher maintenance dosages of steroids was common, requiring the administration of high perioperative doses of corticosteroids.",
"   </p>",
"   <p>",
"    Currently, with the advent of more potent maintenance immunosuppressive agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ), maintenance corticosteroids are either avoided entirely or the doses are markedly reduced. Thus, adrenal suppression has become much less of a problem.",
"   </p>",
"   <p>",
"    In general, the administration of high doses of corticosteroids is usually unnecessary and may be relatively contraindicated. Giving such doses is not entirely benign and can occasionally be associated with gastritis, bleeding, induction of diabetes, and worsening of glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) Although cumbersome, not always practical, and somewhat unreliable, the cosyntropin (Cortrosyn&trade;) stimulation test can be used to help assess adrenal reserve. A discussion on how to assess such patients can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The following two regimens may be utilized in patients considered to have suppression of the hypothalamic-pituitary-adrenal axis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach is to provide high doses of glucocorticoid to those with proven or suspected adrenal insufficiency, starting at the time of induction of anesthesia. A continuous infusion of 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      per hour or the equivalent amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      eliminates the possibility of glucocorticoid deficiency as the cause of an adverse event (such as hypotension), thereby allowing the actual cause (hemorrhage or volume depletion) to be identified and treated.",
"      <br/>",
"      <br/>",
"      The glucocorticoid dose can be halved the day after surgery, and the maintenance dosage usually can be resumed the second postoperative day. This amount of glucocorticoid for this amount of time carries a negligible risk of adverse effects; however, prolonged postoperative pharmacologic glucocorticoid therapy can mask symptoms and signs of infection and produce undesirable side effects.",
"     </li>",
"     <li>",
"      The other regimen utilizes parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      \"boosts.\" Generally, 100 mg of hydrocortisone is given intravenously every eight hours perioperatively and the dose is slowly reduced (but not the frequency) until the patient can be switched to his or her regular doses of oral medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For convenience, we administer intermittent, rather than continuous, parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The maintenance immunosuppressive agents that the patient is receiving are continued in the perioperative period; dosage modification is usually unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, chronically immunosuppressed transplant patients may be considered at higher risk to develop infectious complications after surgical, endoscopic, or dental procedures. Routine antibiotic prophylaxis, either with a first generation cephalosporin or, in the case of dental procedures, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , is ordinarily sufficient in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients who receive prophylactic antibiotics within a two hour \"window\" period before the initial incision have lower rates of surgical site infection than patients who receive them either too early or postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two macrolides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , should be avoided in patients being administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , as these antibiotics antagonize the CYP 3A4 enzyme system, leading to elevated levels of cyclosporine and tacrolimus. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is also a macrolide, it does not significantly affect this enzyme system, and its use usually does not alter cyclosporine or tacrolimus levels. Other safe alternatives are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , which also do not significantly affect cyclosporine or tacrolimus levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tissue integrity and wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronically immunosuppressed patients, even those on low doses of corticosteroids, may frequently be noted intraoperatively to have \"weak\" tissues. Although gentle handling of tissues is an old and well-accepted surgical principle, it is particularly important in the technical performance of surgical procedures in transplant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wound healing is generally slower in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, when skin staples are utilized, they may need to be kept in up to three times longer than in non-transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related issue is whether specific immunosuppressive agents may enhance wound healing complications, even during the period immediately post-transplantation. Some evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    may lead to a higher incidence of adverse outcomes in this setting. In a study of 59 and 64 renal transplant recipients receiving a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    - or sirolimus-based immunosuppressive regimen, respectively (plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and corticosteroids in both groups), the incidence of allograft wound complications was significantly higher in the sirolimus group (47 versus 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/8\">",
"     8",
"    </a>",
"    ]. Perigraft fluid collections, superficial wound infections, and incisional hernias were reported. A discussion of the details concerning adverse cutaneous effects with this agent can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPECIFIC SURGICAL PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following illustrates a few specific clinical considerations that may be particularly important in the transplant recipient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal surgical emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of acute abdominal pathology may be masked in transplant patients owing to the administration of chronic immunosuppressive therapy. Although this certainly can occur, a surprising number of patients present in fairly typical and characteristic ways, thereby making the diagnosis relatively straightforward.",
"   </p>",
"   <p>",
"    Nevertheless, when such complications occur, the morbidity and mortality may be significant. In one retrospective survey of 416 patients following renal transplantation, 31 experienced major gastrointestinal complications, including 14, 5, and 2 cases of bowel perforations, acute pancreatitis, and acute appendicitis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/9\">",
"     9",
"    </a>",
"    ]. The mortality rate was 30 percent, which was principally attributed to immunosuppression and sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute appendicitis may be particularly difficult in a renal (or pancreatic) transplant patient in whom the transplanted organ is found in the right lower quadrant. The appendix is generally displaced superiorly by the transplanted organ; thus, the symptoms and signs are uncharacteristic. The appendix is frequently perforated by the time the diagnosis is made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery can affect a kidney (or pancreas) transplant recipient in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perfusion of the allograft may be compromised with cardiopulmonary bypass. The kidney (or pancreas) may sustain an ischemic insult, which may range from a minimal reversible rise in the serum creatinine concentration to complete shutdown of the organ. Although the latter is unusual, patients with impaired renal function are more likely to sustain damage to the kidney than those with normal renal function.",
"     </li>",
"     <li>",
"      In the unstable cardiac surgical patient who requires an intraaortic balloon pump, placement of the pump on the side of the renal allograft will result in arterial thrombosis. Although it seems to be so obvious a point as not to require comment, this complication can occur and has occurred; thus, avoiding the groin on the side of the kidney is critically important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abdominal aortic aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of an abdominal aortic aneurysm (AAA) routinely requires cross-clamping of the abdominal aorta; this allows the vascular prosthesis to be anastomosed to the proximal and distal aorta (or iliac or femoral arteries). To avoid interruption of the arterial blood supply to the transplanted kidney, temporary bypass may be required, usually from the ipsilateral axillary artery to the femoral artery. This will allow precise, unhurried repair of the aneurysm and eliminate the risk of allograft thrombosis. However, some vascular surgeons believe that there is enough collateral flow to allow AAA repair without a temporary shunt. In addition, a temporary shunt may become completely unnecessary with the advent of endovascular AAA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10133/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29690027\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increasing number of recipients require medical care not specifically related to their transplanted organ. Some require elective or emergency surgery. Many of the principles of peri- and intraoperative management are the same in transplant and non-transplant patients. However, there are a few important differences. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General non-transplant surgical considerations in the kidney transplant recipient include issues relating to corticosteroids, antibiotic prophylaxis, and tissue integrity and wound healing. Specific surgical problems include gastrointestinal surgical emergencies, cardiac surgery, and abdominal aortic aneurysm surgery. Thus, kidney allograft recipients who are undergoing non-transplant surgery may have particular considerations with regard to immunosuppression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      technical issues. It is strongly recommended that the transplant center be consulted prior to any planned surgical intervention in kidney transplant recipients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Specific surgical problems'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/1\">",
"      WOOD JB, FRANKLAND AW, JAMES VH, LANDON J. A RAPID TEST OF ADRENOCORTICAL FUNCTION. Lancet 1965; 1:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/2\">",
"      Grieg, WR, Jasani, MK, Boyle, JA, Maxwell, JD. Corticotrophin stimulation tests. Mem Soc Endocrinol 1968; 17:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/3\">",
"      Speckart PF, Nicoloff JT, Bethune JE. Screening for adrenocortical insufficiency with cosyntropin (synthetic ACTH). Arch Intern Med 1971; 128:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/4\">",
"      Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49:1011.",
"     </a>",
"    </li>",
"    <li>",
"     Kusne, S, Manez, R. Infectious Complications. In: Renal Transplantation, Shapiro, R, Simmons, RL, Starzl, TE (Eds), Stamford, Connecticut, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/6\">",
"      MEADOWS EC, PRUDDEN JF. A study of the influence of adrenal steroids on the strength of healing wounds; preliminary report. Surgery 1953; 33:841.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett, BC, Vivas, CA. Postoperative management of the renal transplant recipient. In: Renal Transplantation, Shapiro, R, Simmons, RL, Starzl, TE (Eds), Stamford, Connecticut, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/8\">",
"      Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10133/abstract/9\">",
"      Bardaxoglou E, Maddern G, Ruso L, et al. Gastrointestinal surgical emergencies following kidney transplantation. Transpl Int 1993; 6:148.",
"     </a>",
"    </li>",
"    <li>",
"     Makaroun, M, University of Pittsburgh Medical Center, 2008, personal communication.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7317 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10133=[""].join("\n");
var outline_f9_57_10133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29690027\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tissue integrity and wound healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECIFIC SURGICAL PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal surgical emergencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29690027\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=related_link\">",
"      Risk factors for cardiovascular disease in the renal transplant recipient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_57_10134="Dress 3";
var content_f9_57_10134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse, confluent, and infiltrated erythematous rash in a patient with DRESS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10134=[""].join("\n");
var outline_f9_57_10134=null;
var title_f9_57_10135="HLA-B27 induce AS";
var content_f9_57_10135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Three different HLA-B27 structures and hypotheses as to how they might induce disease processes in ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HLA-B27 are first generated as free heavy chains, which inside the cells become associated and folded with the &beta;2-microglobulin and antigenic peptide, and then become expressed on the cell surface as a trimolecular complex. It can also be expressed on the cell surface as homodimers of heavy chains without the &beta;2-microglobulin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: MacMillan Publishers Ltd: Tam, LS, Jieruo, G, Yu, D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010; 6:399. Copyright &copy; 2010 MacMillan Publishers Ltd.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10135=[""].join("\n");
var outline_f9_57_10135=null;
var title_f9_57_10136="Chapter 12A: Distribution of potassium between the cells and ECF";
var content_f9_57_10136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 12A: Distribution of potassium between the cells and ECF",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10136/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/57/10136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 15, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total body K+ stores in a normal adult are approximately 3000 to 4000 meq (50 to 55",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    body weight). In contrast to Na+, which is restricted primarily to the extracellular fluid (ECF), K+ is basically an intracellular cation, with 98 percent of body K+ being located in the cells. This can be appreciated from the disparity between the K+ concentrations in the two compartments: cell K+ concentration of 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    versus extracellular (and plasma) K+ concentration of only 4 to 4.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The location of Na+ and K+ in the different fluid compartments is maintained by the active Na+-K+-ATPase pump in the cell membrane, which pumps Na+ out of and K+ into the cell in a 3:2 ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTIONS OF POTASSIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium has two major physiologic functions. First, it plays an important role in cell metabolism, participating in the regulation of such processes as protein and glycogen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, a variety of cell functions may become impaired in conditions of K+ imbalance. As an example, patients with marked K+ depletion often complain of polyuria (increased urine output). This is due in part to a reduced ability to concentrate the urine, resulting from decreased responsiveness to antidiuretic hormone (ADH) (",
"    <a class=\"graphic graphic_figure graphicRef65801 \" href=\"UTD.htm?26/39/27261\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Second, the ratio of the K+ concentrations in the cell and the ECF is the major determinant of the resting membrane potential (Em) across the cell membrane. This relationship can be expressed by the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; r [K+]cell &nbsp;+ &nbsp;0.01 [Na+]cell",
"    <br/>",
"    (Eq. 1) &nbsp; &nbsp;Em &nbsp; = &nbsp; &nbsp; - 61 log &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; r [K+]ecf &nbsp;+ &nbsp;0.01 [Na+]ecf",
"   </p>",
"   <p>",
"    where r is the",
"    <span class=\"nowrap\">",
"     Na+/K+",
"    </span>",
"    active transport ratio of 3:2, and 0.01 is the relative membrane permeability of Na+ to K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/4\">",
"     4",
"    </a>",
"    ]. It is the resting potential that sets the stage for the generation of the action potential that is essential for normal neural and muscular function. Thus, both hypokalemia (low plasma K+ concentration) and hyperkalemia (high plasma K+ concentration) can result in potentially fatal muscle paralysis and cardiac arrhythmias, in part by altering conduction in skeletal and cardiac muscle.",
"   </p>",
"   <p>",
"    The remainder of this chapter will deal with the two functions responsible for the maintenance of a normal plasma K+ concentration: (1) the distribution of K+ between the cells and the extracellular fluid; and (2) the urinary excretion of the K+ added to the extracellular fluid from the diet and endogenous cellular breakdown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DISTRIBUTION OF POTASSIUM BETWEEN CELLS AND EXTRACELLULAR FLUID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulation of the internal distribution of K+ must be extremely efficient, since the movement of as little as 1.5 to 2 percent of the cell K+ into the ECF can result in a potentially fatal increase in the plasma K+ concentration to as high as 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more. A variety of factors, both physiologic and pathologic, can influence this process (",
"    <a class=\"graphic graphic_table graphicRef79106 \" href=\"UTD.htm?2/41/2715\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The most important in the day-to-day regulation of K+ balance are Na+-K+-ATPase (the activity of which is increased by catecholamines and insulin) and the plasma K+ concentration itself [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sodium-potassium-ATPase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal K+ distribution is primarily determined by the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1\">",
"     1",
"    </a>",
"    ]. The activity of this pump is regulated by several factors, including thyroid hormone and, with regard to K+ homeostasis, catecholamines, insulin, and the state of K+ balance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example of its importance in humans can be seen when Na+-K+-ATPase is partially inhibited by a massive overdose of digitalis, a drug useful in the treatment of heart disease. In this setting, marked hyperkalemia (plasma K+ concentration up to 13.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can occur, because of the relative inability of K+ to enter the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The result is somewhat different when the pump is impaired chronically [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1\">",
"     1",
"    </a>",
"    ]. In a variety of chronic diseases such as renal failure and heart failure, Na+-K+-ATPase activity is often reduced, due to an acquired defect in cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As a result, K+ leaves and Na+ enters the cells down passive gradients. The net effect is as much as a 10 to 15 percent reduction in total body K+ stores in association with a high cell Na+ concentration, a low cell K+ concentration, but no change in the plasma K+ concentration because the excess extracellular K+ has time to be excreted in the urine if renal function is adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. In patients with renal failure, however, the decrease in pump activity can contribute to the development of hyperkalemia.",
"   </p>",
"   <p>",
"    In addition to the basal distribution of K+, there is a frequent exchange of K+ between the ECF and the cells because of variations in dietary intake. As an example, three large glasses of orange juice contain approximately 40 meq of K+. The normal extracellular fluid volume is roughly 17 liters in a 70-kg man. Thus, there would be a potentially dangerous 2.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (40 meq &divide; 17 L) increase in the plasma K+ concentration if the ingested K+ remained in the extracellular fluid. This is prevented by the rapid entry of most of the K+ load into the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/6\">",
"     6",
"    </a>",
"    ]. Within six to eight hours, K+ balance is then restored by the urinary excretion of the excess K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Although the initial elevation in the plasma K+ concentration directly promotes the intracellular movement of K+, both catecholamines and insulin also play an important role in this process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Catecholamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catecholamines can affect internal K+ distribution, with alpha-receptors impairing and &szlig;2-receptors promoting the cellular entry of K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The &szlig;2-receptor-induced stimulation of K+ uptake is mediated at least in part by activation of the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. This appears to reflect a permissive action of basal catecholamine levels, since there is no evidence that a K+ load increases the release of epinephrine or norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic importance of catecholamines in humans can be illustrated by two observations. First, the increment in the plasma K+ concentration after a K+ load is greater and more prolonged if the subject has been pretreated with a &szlig;-adrenergic blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef62538 \" href=\"UTD.htm?29/51/30525\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/14,16,18,19\">",
"     14,16,18,19",
"    </a>",
"    ]. This difference is due to a substantial reduction in cellular K+ uptake, most of which normally occurs in skeletal muscle and the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second, the release of epinephrine during a stress response, such as coronary ischemia, can acutely lower the plasma K+ concentration by approximately 0.5 to 0.6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/20\">",
"     20",
"    </a>",
"    ]. In this setting, the hypokalemic response also may be mediated by a rise in insulin release. Increased &szlig;2-adrenergic activity enhances insulin secretion both by direct stimulation of the pancreas and by enhancing glycolysis, leading to a rise in the plasma glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/21\">",
"     21",
"    </a>",
"    ]. The net effect can, in patients with preexistent mild diuretic-induced hypokalemia, result in an acute reduction in the plasma K+ concentration to below 2.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef57078 \" href=\"UTD.htm?26/12/26829\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A similar hypokalemic effect can be induced by the administration of a &szlig;2-adrenergic agonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    to treatment asthma or heart failure or to prevent premature labor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In heart failure, for example, the acute 0.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    fall in the plasma potassium concentration can enhance the tendency to ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin promotes the entry of K+ into skeletal muscle and the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], again by increasing Na+-K+-ATPase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. This property, which is independent of any effect on glucose transport [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/25\">",
"     25",
"    </a>",
"    ], plays a physiologic role in the regulation of the plasma K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/5,6,26,28\">",
"     5,6,26,28",
"    </a>",
"    ]. As an example, the ingestion of glucose (which enhances endogenous insulin release) minimizes the rise in the plasma K+ concentration induced by concurrent K+ intake (",
"    <a class=\"graphic graphic_figure graphicRef65186 \" href=\"UTD.htm?40/8/41101\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the ability to handle a K+ load is impaired with insulin deficiency (as might be induced by an infusion of somatostatin). In this setting, the baseline plasma K+ concentration rises (by 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    and a K+ load induces a greater than normal degree of hyperkalemia. These changes are reversed by an infusion of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/26\">",
"     26",
"    </a>",
"    ]. Furthermore, no alteration in K+ balance is seen when somatostatin is used in type 1 (insulin-dependent) diabetes mellitus, since these patients have little or no endogenous insulin and somatostatin is therefore without effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with catecholamines, it appears that basal insulin levels permissively allow K+ entry into cells. The possible presence of a positive feedback loop, in which K+ stimulates the release of insulin, is uncertain. Initial studies demonstrated a rise in the plasma insulin concentration after an increase in the plasma K+ concentration of more than 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/28\">",
"     28",
"    </a>",
"    ]; in comparison, a more physiologic elevation of 0.3 to 0.7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is without apparent effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. It is possible, however, that small elevations in the plasma K+ concentration can increase insulin release into the portal vein, thereby promoting hepatic K+ uptake without affecting the peripheral plasma insulin level [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its physiologic role, the effect of insulin on K+ distribution is useful in the treatment of hyperkalemia. Giving either glucose (to enhance endogenous release) or insulin (with glucose to prevent hypoglycemia) can acutely lower the plasma K+ concentration by driving K+ into the cells (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/31\">",
"     31",
"    </a>",
"    ]. On the other hand, treating hypokalemia by the administration of intravenous K+ in a dextrose-containing solution can cause an initial further reduction in the plasma K+ concentration and the possible induction of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/32\">",
"     32",
"    </a>",
"    ]. This effect of insulin on K+ distribution lasts only several hours, since other factors (including the plasma K+ concentration itself) then cause K+ to move back into the extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To summarize, the primary physiologic effect of insulin and catecholamines is to facilitate the disposition of a K+ load. Although a deficiency of these hormones may initially elevate the baseline plasma K+ concentration, this is usually transient since the excess K+ is readily excreted in the urine. Thus, the fasting plasma K+ concentration is typically normal in patients treated with &szlig;-adrenergic blockers and in patients with type 1 diabetes mellitus given enough insulin to prevent marked hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/14,18,26\">",
"     14,18,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plasma potassium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of insulin deficiency and sympathetic blockade impairs but does not prevent the intracellular movement of K+ after a K+ load, indicating that other factors must also be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/33\">",
"     33",
"    </a>",
"    ]. One of these is the plasma K+ concentration itself. After a K+ load, for example, the initial elevation in the plasma K+ concentration promotes K+ entry into the cells, perhaps by passive mechanisms. Conversely, the loss of K+ from the ECF due to gastrointestinal or renal losses results first in a fall in the plasma K+ concentration and then in the movement of K+ from the cells into the ECF to minimize the degree of hypokalemia.",
"   </p>",
"   <p>",
"    The net effect is that, in most situations, the plasma K+ concentration varies directly with body K+ stores, decreasing with K+ depletion and increasing with K+ retention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/6\">",
"     6",
"    </a>",
"    ]. There are, however, some exceptions to this rule, including chronic diseases as described above (in which Na+-K+-ATPase activity appears to be reduced), exercise, changes in the extracellular pH or rate of cell breakdown, and an increase in the effective plasma osmolality. In these disorders, clinically significant hyperkalemia or hypokalemia may result from redistribution of K+ between the cells and the ECF without change in body K+ stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium is normally released from muscle cells during exercise. This response may in part reflect a delay between K+ exit during depolarization and subsequent reuptake by the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1\">",
"     1",
"    </a>",
"    ]. With moderate to severe exercise, however, an additional factor may become important. Muscle cells have ATP-dependent K+ channels, in which ATP reduces the number of open channels. Thus, a reduction in ATP levels with marked exercise can open up more channels, thereby promoting K+ release from the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The release of K+ during exercise may have a physiologic function. The local increase in the plasma K+ concentration has a vasodilatory effect which contributes to the enhanced blood flow (and therefore energy delivery) to the exercising muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This response is impaired by K+ depletion, an abnormality that may contribute to ischemic muscle injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The elevation in the systemic plasma K+ concentration (which is less than that in the local circulation) is related to the degree of exercise: 0.3 to 0.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with slow walking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/36\">",
"     36",
"    </a>",
"    ], 0.7 to 1.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with moderate exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/16,37,38\">",
"     16,37,38",
"    </a>",
"    ], and as much as 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with severe exercise to exhaustion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These changes are reversed after several minutes of rest [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/37,39\">",
"     37,39",
"    </a>",
"    ] and may be associated with a mild rebound hypokalemia of 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below the baseline level [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise-induced hyperkalemia is attenuated by physical conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/1,41\">",
"     1,41",
"    </a>",
"    ]. Conditioning enhances both the resting cell K+ concentration and Na+-K+-ATPase activity (via an unknown mechanism); the latter adaptation may be responsible for the lesser degree of K+ release during exercise.",
"   </p>",
"   <p>",
"    The hyperkalemia associated with exercise is generally mild and produces no symptoms. However, it can lead to a potentially dangerous elevation in the plasma K+ concentration in the presence of some other abnormality in K+ handling. As an example, severe exercise in patients taking a &szlig;-adrenergic blocker can acutely raise the plasma K+ concentration by 1.5 to as much as 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/16,40\">",
"     16,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of exercise can also affect the",
"    <strong>",
"     measurement",
"    </strong>",
"    of the plasma K+ concentration. After a tourniquet is applied, the patient is frequently instructed to repeatedly clench and unclench his or her fist in an attempt to increase local blood flow and make the veins more apparent for venipuncture. This can result in as much as a 1 to 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    elevation in the plasma K+ concentration, leading to erroneous evaluation of the state of K+ balance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extracellular pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in acid-base balance may have important effects on the plasma K+ concentration. particularly in those forms of metabolic acidosis (such as renal failure) that are not due to the accumulation of organic acids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43\">",
"     43",
"    </a>",
"    ]. In this setting, 60 percent or more of the excess H+ ions is buffered in the cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23224?source=see_link\">",
"     \"Chapter 10B: Buffers\"",
"    </a>",
"    .) Since the major extracellular anion Cl- enters the cells only to a limited degree, electroneutrality is maintained by the movement of cellular K+ and Na+ into the ECF (",
"    <a class=\"graphic graphic_figure graphicRef68866 \" href=\"UTD.htm?9/25/9628\">",
"     figure 5",
"    </a>",
"    ). The result is a variable increase in the plasma K+ concentration of 0.2 to 1.7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 0.1-unit fall in the extracellular pH (the latter is usually measured clinically on an arterial blood specimen) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (The plasma Na+ concentration may also rise, but an elevation of a few milliequivalents per liter is not physiologically important, since the normal value is 140",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    not 4 to 4.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    as with potassium.)",
"   </p>",
"   <p>",
"    The wide variability in the degree of hyperkalemia is probably related in part to the common presence of other factors that can influence K+ homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. As examples, diarrhea and renal tubular acidosis are associated with increased gastrointestinal and urinary K+ losses, respectively; the negative K+ balance in these disorders often leads to hypokalemia despite the presence of metabolic acidosis. It should be emphasized, however, that there is still relative hyperkalemia in this setting, since correction of the acidemia will lead to a further reduction in the plasma K+ concentration unless K+ supplements are administered.",
"   </p>",
"   <p>",
"    The relationship between acidemia and K+ distribution is also not predictable in the organic acidoses (lactic acidosis and ketoacidosis). In these conditions, the fall in pH appears to be less likely to elevate the plasma K+ concentration&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43,45-47\">",
"     43,45-47",
"    </a>",
"    ]. As depicted in Figure 6 (",
"    <a class=\"graphic graphic_figure graphicRef57068 \" href=\"UTD.htm?3/13/3293\">",
"     figure 6",
"    </a>",
"    ), for example, the administration of HCl, but not lactic acid, causes hyperkalemia in dogs. The reason for this difference is not known. One possibility is that the organic anion (such as lactate or &szlig;-hydroxybutyrate in ketoacidosis) is able to follow H+ into the cell, thereby removing the necessity for redistribution of K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43,48\">",
"     43,48",
"    </a>",
"    ]. Alternatively, experimental studies suggest that organic anions may act as substrates for the pancreatic &szlig; cell, leading to the release of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/49\">",
"     49",
"    </a>",
"    ]. Insulin then drives K+ into the cells, counteracting the direct effect of acidemia. However, the applicability of these findings to humans remains to be proven, especially in diabetic ketoacidosis where insulin deficiency is the primary abnormality.",
"   </p>",
"   <p>",
"    &dagger; Hyperkalemia is a common finding in ketoacidosis and lactic acidosis, but factors other than acidemia are probably of primary importance. In ketoacidosis, for example, both insulin deficiency and hyperosmolality (see below) promote K+ movement from the cells into the ECF. Thus, the incidence of hyperkalemia is similar in diabetic ketoacidosis and in nonketotic hyperglycemia, where the systemic pH is relatively normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The change in the plasma K+ concentration is also much less prominent in metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43\">",
"     43",
"    </a>",
"    ]. Although H+ tends to move out of and K+ into the cells in this disorder, there is generally only a small reduction in the plasma K+ concentration (unless there are concomitant urinary or gastrointestinal K+ losses). This relative lack of effect may result in part from less intracellular buffering (and therefore less transcellular H+ movement) in metabolic alkalosis than in metabolic acidosis (33 percent versus 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/51\">",
"     51",
"    </a>",
"    ]. Large changes in the plasma K+ concentration are also not seen in respiratory acidosis or alkalosis; why this occurs is not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperosmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma K+ concentration may rise by as much as 0.4 to 0.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 10",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    elevation in the effective plasma osmolality (due to hyperglycemia, hypernatremia, or the administration of hypertonic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/30,52-55\">",
"     30,52-55",
"    </a>",
"    ]. Hyperosmolality results in the diffusion of water out of cells down an osmotic gradient. In this setting, two factors can contribute to the parallel movement of K+ into the ECF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The loss of water raises the K+ concentration within the cell, thereby creating a favorable gradient for passive potassium exit through potassium channels in the cell membrane.",
"     </li>",
"     <li>",
"      The frictional forces between the solvent (water) and solute can result in K+ being carried along with water through the water channels in the cell membrane. This phenomenon, called solvent drag, is independent of concentration or electrical gradients for K+ or other solutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common clinical example of this phenomenon is the increase in the plasma K+ concentration that commonly accompanies hyperglycemia in uncontrolled diabetes mellitus (",
"    <a class=\"graphic graphic_figure graphicRef64207 \" href=\"UTD.htm?13/22/13677\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ]. The hyperkalemia partially dissipates with time as some of the excess extracellular K+ is excreted in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rate of cell breakdown and production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any condition which enhances cell breakdown (such as severe trauma or the tumor lysis syndrome) results in the release of K+ (and other intracellular solutes) into the ECF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The degree to which this will elevate the plasma K+ concentration is related to the ability of other cells to take up the excess K+ and of the kidney to augment K+ excretion.",
"   </p>",
"   <p>",
"    On the other hand, conditions associated with a rapid increase in cell production can result in K+ movement into the cells and hypokalemia. This sequence has been observed after the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    or vitamin B12 to patients with megaloblastic anemia, who typically respond with an acute and marked increase in the production of red cells and platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10136/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the basal state, the distribution of K+ between the cells and the ECF is primarily governed by the Na+-K+-ATPase pump in the cell membrane. Although they are not so important in the basal state, catecholamines and insulin play a major role in promoting the cellular uptake of K+ after a dietary load. This prevents a potentially serious elevation in the plasma K+ concentration until the kidney can restore K+ balance by excreting the excess K+. These hormones appear to act permissively, since their rate of secretion is not enhanced by K+.",
"   </p>",
"   <p>",
"    The plasma K+ concentration may also directly influence K+ distribution as K+ moves into the cells with hyperkalemia and out of the cells with hypokalemia. As a result, the plasma K+ concentration generally reflects the state of total body K+ stores. This relationship may be disturbed, however, in a variety of conditions (such as exercise, certain forms of metabolic acidosis, or hyperosmolality) in which internal redistribution can alter the plasma K+ concentration without a similar change in K+ stores.",
"   </p>",
"   <p>",
"    This text is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/1\">",
"      Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/2\">",
"      Doucet A. Function and control of Na-K-ATPase in single nephron segments of the mammalian kidney. Kidney Int 1988; 34:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/3\">",
"      Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med 1982; 72:521.",
"     </a>",
"    </li>",
"    <li>",
"     DeVoe RD, Maloney PC. Principles of cell homeostasis. in Medical Physiology 1980; 14th ed, Mountcastle, VB (ed), Mosby, St. Louis.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/5\">",
"      Brown RS. Extrarenal potassium homeostasis. Kidney Int 1986; 30:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/6\">",
"      Sterns RH, Cox M, Feig PU, Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore) 1981; 60:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/7\">",
"      Reza MJ, Kovick RB, Shine KI, Pearce ML. Massive intravenous digoxin overdosage. N Engl J Med 1974; 291:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/8\">",
"      Kaji D, Thomas K. Na+-K+ pump in chronic renal failure. Am J Physiol 1987; 252:F785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/9\">",
"      Edmondson RP, Thomas RD, Hilton PJ, et al. Leucocyte electrolytes in cardiac and non-cardiac patients receiving diuretics. Lancet 1974; 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/10\">",
"      CASEY TH, SUMMERSKILL WH, ORVIS AL. BODY AND SERUM POTASSIUM IN LIVER DISEASE. I. RELATIONSHIP TO HEPATIC FUNCTION AND ASSOCIATED FACTORS. Gastroenterology 1965; 48:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/11\">",
"      Bilbrey GL, Carter NW, White MG, et al. Potassium deficiency in chronic renal failure. Kidney Int 1973; 4:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/12\">",
"      Winkler AW, Hoff HE, Smith PK. THE TOXICITY OF ORALLY ADMINISTERED POTASSIUM SALTS IN RENAL INSUFFICIENCY. J Clin Invest 1941; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/13\">",
"      DeFronzo RA, Taufield PA, Black H, et al. Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med 1979; 90:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/14\">",
"      DeFronzo RA, Bia M, Birkhead G. Epinephrine and potassium homeostasis. Kidney Int 1981; 20:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/15\">",
"      Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983; 309:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/16\">",
"      Williams ME, Gervino EV, Rosa RM, et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 1985; 312:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/17\">",
"      Clausen T, Flatman JA. Effects of insulin and epinephrine on Na+-K+ and glucose transport in soleus muscle. Am J Physiol 1987; 252:E492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/18\">",
"      Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980; 302:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/19\">",
"      Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med 1993; 94:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/20\">",
"      Struthers AD, Whitesmith R, Reid JL. Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia. Lancet 1983; 1:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/21\">",
"      Schnack C, Podolsky A, Watzke H, et al. Effects of somatostatin and oral potassium administration on terbutaline-induced hypokalemia. Am Rev Respir Dis 1989; 139:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/22\">",
"      Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med 1989; 86:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/23\">",
"      Braden GL, von Oeyen PT, Germain MJ, et al. Ritodrine- and terbutaline-induced hypokalemia in preterm labor: mechanisms and consequences. Kidney Int 1997; 51:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/24\">",
"      Goldenberg IF, Olivari MT, Levine TB, Cohn JN. Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol 1989; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/25\">",
"      ZIERLER KL, RABINOWITZ D. EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE. J Clin Invest 1964; 43:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/26\">",
"      DeFronzo RA, Sherwin RS, Dillingham M, et al. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings. J Clin Invest 1978; 61:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/27\">",
"      Lytton J, Lin JC, Guidotti G. Identification of two molecular forms of (Na+,K+)-ATPase in rat adipocytes. Relation to insulin stimulation of the enzyme. J Biol Chem 1985; 260:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/28\">",
"      Dluhy RG, Axelrod L, Williams GH. Serum immunoreactive insulin and growth hormone response to potassium infusion in normal man. J Appl Physiol 1972; 33:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/29\">",
"      Cox M, Sterns RH, Singer I. The defense against hyperkalemia: the roles of insulin and aldosterone. N Engl J Med 1978; 299:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/30\">",
"      Kurtzman NA, Gonzalez J, DeFronzo R, Giebisch G. A patient with hyperkalemia and metabolic acidosis. Am J Kidney Dis 1990; 15:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/31\">",
"      Blumberg A, Weidmann P, Shaw S, Gn&auml;dinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med 1988; 85:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/32\">",
"      KUNIN AS, SURAWICZ B, SIMS EA. Decrease in serum potassium concentrations and appearance of cardiac arrhythmias during infusion of potassium with glucose in potassium-depleted patients. N Engl J Med 1962; 266:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/33\">",
"      DeFronzo RA, Lee R, Jones A, Bia M. Effect of insulinopenia and adrenal hormone deficiency on acute potassium tolerance. Kidney Int 1980; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/34\">",
"      Daut J, Maier-Rudolph W, von Beckerath N, et al. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990; 247:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/35\">",
"      Knochel JP, Schlein EM. On the mechanism of rhabdomyolysis in potassium depletion. J Clin Invest 1972; 51:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/36\">",
"      Sassard J, Vincent M, Annat G, Bizollon CA. A kinetic study of plasma renin and aldosterone during changes of posture in man. J Clin Endocrinol Metab 1976; 42:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/37\">",
"      Struthers AD, Quigley C, Brown MJ. Rapid changes in plasma potassium during a game of squash. Clin Sci (Lond) 1988; 74:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/38\">",
"      Thomson A, Kelly DT. Exercise stress-induced changes in systemic arterial potassium in angina pectoris. Am J Cardiol 1989; 63:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/39\">",
"      Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/40\">",
"      Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 2:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/41\">",
"      Knochel JP, Blachley JD, Johnson JH, Carter NW. Muscle cell electrical hyperpolarization and reduced exercise hyperkalemia in physically conditioned dogs. J Clin Invest 1985; 75:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/42\">",
"      Don BR, Sebastian A, Cheitlin M, et al. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990; 322:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/43\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/44\">",
"      Magner PO, Robinson L, Halperin RM, et al. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis 1988; 11:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/45\">",
"      Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/46\">",
"      Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med 1977; 297:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/47\">",
"      Perez GO, Oster JR, Vaamonde CA. Serum potassium concentration in acidemic states. Nephron 1981; 27:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/48\">",
"      Graber M. A model of the hyperkalemia produced by metabolic acidosis. Am J Kidney Dis 1993; 22:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/49\">",
"      Adrogu&eacute; HJ, Chap Z, Ishida T, Field JB. Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs. J Clin Invest 1985; 75:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/50\">",
"      Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     Pitts RF. Physiology of the Kidney and Body Fluids,. Year Book, Chicago 1974; Chap 11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/52\">",
"      Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/53\">",
"      Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/54\">",
"      Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/55\">",
"      Moreno M, Murphy C, Goldsmith C. Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. J Lab Clin Med 1969; 73:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/56\">",
"      Arseneau JC, Bagley CM, Anderson T, Canellos GP. Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet 1973; 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/57\">",
"      Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/58\">",
"      Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol 1994; 17:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10136/abstract/59\">",
"      Lawson DH, Murray RM, Parker JL. Early mortality in the megaloblastic anaemias. Q J Med 1972; 41:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7263 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10136=[""].join("\n");
var outline_f9_57_10136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTIONS OF POTASSIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DISTRIBUTION OF POTASSIUM BETWEEN CELLS AND EXTRACELLULAR FLUID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sodium-potassium-ATPase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Catecholamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plasma potassium concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extracellular pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperosmolality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rate of cell breakdown and production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7263|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/39/27261\" title=\"figure 1\">",
"      Hypokalemia and DI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/51/30525\" title=\"figure 2\">",
"      Beta blocker and potassium load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/12/26829\" title=\"figure 3\">",
"      Epinephrine and plasma K",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/8/41101\" title=\"figure 4\">",
"      Insulin and potassium load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/25/9628\" title=\"figure 5\">",
"      Acidosis and K distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/13/3293\" title=\"figure 6\">",
"      Acidosis and K balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/22/13677\" title=\"figure 7\">",
"      Glucose induced hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/41/2715\" title=\"table 1\">",
"      Potassium distribution",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23224?source=related_link\">",
"      Chapter 10B: Buffers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_57_10137="Complications of endoscopic esophageal stricture dilation";
var content_f9_57_10137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of endoscopic esophageal stricture dilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10137/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10137/contributors\">",
"     Moises Guelrud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10137/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/57/10137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/57/10137/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/57/10137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of benign esophageal strictures typically involves dilation combined with acid suppressive therapy. Advances in endoscopic equipment and dilators have improved the safety of esophageal dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/1\">",
"     1",
"    </a>",
"    ], but esophageal dilation may lead to complications even in the most experienced hands. Awareness of the complications associated with dilation permits early recognition and reduces morbidity and mortality.",
"   </p>",
"   <p>",
"    This topic will review the major complications associated with esophageal stricture dilation. The techniques used for the dilation of benign esophageal strictures, the approach to patients with non-iatrogenic esophageal perforations, and the complications associated with upper endoscopy in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29606?source=see_link\">",
"     \"Boerhaave's syndrome: Effort rupture of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/48/32518?source=see_link\">",
"     \"Management of non-iatrogenic traumatic esophageal perforations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=see_link&amp;anchor=H67011650#H67011650\">",
"     \"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL PERFORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complication of esophageal dilation is esophageal perforation, which is associated with a mortality rate of approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of perforation is influenced by the etiology of the stricture, the experience of the endoscopist, and the techniques and equipment used. In general, perforation rates associated with esophageal stricture dilation are low, unlike procedures such as pneumatic dilation for achalasia, where perforations are estimated to complicate three to five percent of procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=see_link&amp;anchor=H12#H12\">",
"     \"Pneumatic dilation and botulinum toxin injection for achalasia\", section on 'Esophageal perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies suggest that the perforation rate associated with the dilation of benign strictures is between 0.1 and 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The perforation rate was 0.1 percent per session in a report from 1999 that looked at 1043 dilation sessions using Eder-Puestow or Savary dilators in 153 patients (over half of whom had peptic strictures) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar perforation rate was found in a report in which 1071 benign strictures were dilated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/6\">",
"       6",
"      </a>",
"      ]. The overall complication rate for patients with benign strictures was 0.18 percent, with a perforation rate of 0.09 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors for esophageal perforation have been recognized, although the magnitude of risk is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/5,9-12\">",
"     5,9-12",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A malignant stricture",
"     </li>",
"     <li>",
"      Severe esophagitis",
"     </li>",
"     <li>",
"      Prior radiation therapy",
"     </li>",
"     <li>",
"      A history of caustic ingestion",
"     </li>",
"     <li>",
"      Complex (tortuous) or long strictures",
"     </li>",
"     <li>",
"      Presence of esophageal diverticula",
"     </li>",
"     <li>",
"      Inexperienced operator",
"     </li>",
"     <li>",
"      A large hiatal hernia",
"     </li>",
"     <li>",
"      Use of high inflation pressures with balloon dilation",
"     </li>",
"     <li>",
"      A history of previous esophageal perforation",
"     </li>",
"     <li>",
"      A history of prior esophageal surgery (such as for trauma or a congenital abnormality)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eosinophilic esophagitis has generally been considered a risk factor for deep mucosal tears and esophageal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. However, studies examining whether patients with eosinophilic esophagitis are at increased risk have had variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review found only one perforation associated with 671 esophageal dilations (0.1 percent) in patients with eosinophilic esophagitis, a rate that is similar to the expected perforation rate for patients without eosinophilic esophagitis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second report not included in the systematic review found that there were no perforations among 207 patients with eosinophilic esophagitis who underwent esophageal dilation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, an increased perforation rate was noted in third study in which there were 3 perforations among 293 dilations (1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the variable results, we believe it is prudent to continue to consider patients with eosinophilic esophagitis as being at increased risk for perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=see_link&amp;anchor=H209738#H209738\">",
"     \"Treatment of eosinophilic esophagitis\", section on 'Esophageal dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with an esophageal perforation present for evaluation within 24 hours of the injury, though in some cases the presentation may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/19\">",
"     19",
"    </a>",
"    ]. The clinical features of esophageal perforation depend upon the location of the perforation (cervical, intrathoracic, or intra-abdominal), the degree of leakage, and the time elapsed since the injury occurred. Cervical perforations are typically less severe than intrathoracic or intra-abdominal perforations, though contamination of the mediastinum can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptom is pain, occurring in more than 70 percent of patients with intrathoracic perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients may develop tachycardia, tachypnea, and fever, which can progress rapidly to sepsis and shock. Auscultation of the chest in patients with mediastinal emphysema (pneumomediastinum) may reveal a crunching noise (\"Hamman's sign\").",
"   </p>",
"   <p>",
"    Additional signs and symptoms may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical perforation may be associated with neck pain, tenderness of the sternocleidomastoid muscle, dysphonia, hoarseness, cervical dysphagia, and cervical subcutaneous emphysema.",
"     </li>",
"     <li>",
"      Intrathoracic perforation results in contamination of the mediastinum and may also extend into the pleural cavity (most often on the left). It is most commonly associated with chest, back, or epigastric pain that is exacerbated with inspiration and swallowing. Patients may also have dysphagia, odynophagia, dyspnea, hematemesis, cyanosis, and, rarely, pericardial tamponade if the perforation involves the posterior pericardium. Mediastinal inflammation may eventually result in cervical subcutaneous emphysema. Due to negative intrathoracic pressure, gastric contents and bacteria may be drawn into the pleural space. Patients may develop signs of sepsis and shock within hours.",
"     </li>",
"     <li>",
"      Intra-abdominal perforation results in contamination of the peritoneal cavity. Patients may report back pain and an inability to lie supine. In addition, patients often report epigastric pain that may radiate to the shoulder. Patients may also present with an acute (surgical) abdomen. As with intrathoracic perforation, patients may rapidly deteriorate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnostic approach to abdominal pain in adults\", section on 'Surgical abdomen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The laboratory evaluation may reveal a leukocytosis. While not part of the diagnostic workup for an esophageal perforation, pleural fluid collected during thoracentesis may contain undigested food, have a pH less than 6, or have an elevated salivary amylase level [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154482667\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with pain following esophageal dilation have a perforation. Nonspecific chest pain following esophageal dilation is not uncommon, though it is typically mild, self-limited, and lacks the associated signs and symptoms seen with a perforation, such as subcutaneous emphysema. An exception is the pain associated with esophageal dilation with stent placement, which may be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In addition, some patients will complain of abdominal discomfort resulting from air insufflation. Like patients with nonspecific chest pain, the abdominal discomfort is typically mild and transient. (See",
"    <a class=\"local\" href=\"#H154484442\">",
"     'Nonspecific chest pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Chest or abdominal pain may also be seen with disorders such as myocardial infarction, pancreatitis, peptic ulcer perforation, aortic aneurysm dissection, spontaneous pneumothorax, or pneumonia. However, the history of a recent esophageal dilation makes these disorders less likely.",
"   </p>",
"   <p>",
"    In general, an esophageal perforation should be excluded if the patient's pain is moderate to severe, if it fails to improve after one to two hours, or if there are other symptoms suggestive of a perforation. In addition, patients with post-procedure pain should be given nothing by mouth until it is clear that their pain is improving. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An esophageal perforation should be suspected in patients who develop significant neck, chest, or abdominal pain following endoscopy. Generally, the evaluation starts with an examination for signs of a perforation (eg, subcutaneous emphysema), followed by plain thoracic and cervical X-rays. If needed, contrast esophagography or computed tomographic (CT) scanning may be obtained to confirm the diagnosis or to look for intrathoracic and intra-abdominal collections that require drainage. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because delays in diagnosis are associated with higher complication and mortality rates, early diagnosis is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. As an example, in a summary of 390 patients from 11 series, the overall mortality rate for patients who did not receive treatment within 24 hours was 27 percent (range 0 to 46 percent), whereas it was 14 percent (range 0 to 28 percent) for patients who were treated within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150633334\">",
"    <span class=\"h3\">",
"     Thoracic and cervical x-rays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a suspected perforation should undergo thoracic and cervical X-rays (posterior-anterior and lateral films). In addition, if an intra-abdominal perforation is suspected, upright abdominal films should be obtained. Radiographic evidence of emphysema is found subcutaneously in the neck in approximately 95 percent of patients with cervical perforations, and in the mediastinum in approximately 40 percent of patients with intrathoracic perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/29\">",
"     29",
"    </a>",
"    ]. Other findings suggestive of an esophageal perforation include pleural effusions, mediastinal widening, hydrothorax, hydropneumothorax, or subdiaphragmatic air. Mediastinal emphysema may not become visible radiographically for an hour, and pleural effusions and mediastinal widening may take several hours to develop [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150633349\">",
"    <span class=\"h3\">",
"     Contrast esophagography (Gastrografin or barium swallow)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast esophagography usually establishes the diagnosis. The sensitivity of contrast studies depends upon the size and location of the perforation, and the technique used for the study. The studies should be carried out with the patient in the right lateral decubitus position [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/31\">",
"     31",
"    </a>",
"    ]. In many centers, water-soluble contrast agents (eg, Gastrografin&reg;) are used initially. Esophagography with water-soluble contrast will show extravasation on X-ray in 50 percent of patients with cervical perforations and 75 to 80 of patient with thoracic perforations (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71821 \" href=\"UTD.htm?32/2/32814\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/32\">",
"     32",
"    </a>",
"    ]. Water-soluble contrast must be used with care in patients at risk for aspiration, as it can cause severe pneumonitis. In such patients, dilute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    is preferred as the initial contrast agent. In addition, water-soluble contrast should not be used in patients with known or suspected fistulas between the esophagus and the respiratory tract or if respiratory tract perforation is suspected.",
"   </p>",
"   <p>",
"    If the water-soluble contrast study is negative, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    study should be performed. Barium studies will detect 60 percent of cervical perforations and 90 percent of intrathoracic perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. Although barium is superior to water-soluble contrast for demonstrating small perforations, it causes an inflammatory response in mediastinal or pleural cavities and is therefore not used as the primary diagnostic study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150633364\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical suspicion remains high despite negative findings on esophageal contrast studies, or if contrast studies cannot be obtained, computed tomography (CT) scanning should be performed. A CT scan is highly sensitive for detecting extravasated air in soft tissues adjacent to the esophagus or in the mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/35\">",
"     35",
"    </a>",
"    ]. Other findings on CT scan may include esophageal wall thickening, pleural effusions, or periesophageal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/35\">",
"     35",
"    </a>",
"    ]. We agree with the recommendation of some authors that all patients with an esophageal perforation undergo CT scanning to look for intrathoracic and intra-abdominal fluid collections that would require drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154482778\">",
"    <span class=\"h3\">",
"     Flexible upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is generally not used to diagnose a perforation following esophageal dilation (though it may be used in other settings where esophageal perforation is suspected, such as penetrating trauma). Air insufflated during endoscopy may dissect intramurally and cause cervical subcutaneous emphysema. This in turn could suggest a more serious perforation than what is actually present and may result in surgery in a patient who could have been managed medically [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/2\">",
"     2",
"    </a>",
"    ]. However, upper endoscopy may be employed as part of the treatment for the perforation (see",
"    <a class=\"local\" href=\"#H27673437\">",
"     'Endoscopic management'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If a perforation is clearly seen at the time of the index endoscopy, radiographic imaging should still be obtained to assess the extent of the",
"    <span class=\"nowrap\">",
"     perforation/leak,",
"    </span>",
"    or if endoscopic therapy is performed at the time of the perforation, to assess closure of the defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27673362\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with esophageal perforation following esophageal dilation depends upon the severity of the perforation and the elapsed time between the perforation and its diagnosis. Management options include medical management, endoscopic therapy, and surgery.",
"   </p>",
"   <p>",
"    Patients whose perforations are recognized early have a good prognosis and, in many cases, can be managed nonsurgically. By contrast, a delay in diagnosis (particularly beyond 24 hours) usually leads to the need for surgical intervention and is associated with a mortality rate as high as 25 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/33,37\">",
"     33,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of management are to prevent further contamination, treat infection, restore gastrointestinal tract continuity, and provide nutritional support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154482785\">",
"    <span class=\"h3\">",
"     General management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the mortality rate associated with esophageal perforation is high, intensive care unit admission should be considered not only for patients with evidence of hemodynamic compromise, but also for patients with multiple comorbid conditions.",
"   </p>",
"   <p>",
"    Regardless of what management approach is chosen (medical, endoscopic, or surgical), all patients with an esophageal perforation require the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of all oral intake",
"     </li>",
"     <li>",
"      Nutritional support, typically parenteral",
"     </li>",
"     <li>",
"      Intravenous broad spectrum antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intravenous proton pump inhibitor",
"     </li>",
"     <li>",
"      Drainage of fluid",
"      <span class=\"nowrap\">",
"       collections/debridement",
"      </span>",
"      of infected and necrotic tissue if present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, surgical consultation should be obtained for all patients, since patients managed medically or endoscopically may deteriorate and require surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Medical management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150633261\">",
"    <span class=\"h4\">",
"     Patient selection for medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have documented successful nonsurgical management of esophageal perforations in appropriately selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/29,33,37-41\">",
"     29,33,37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics that are associated with favorable outcomes in patients who are managed nonoperatively include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iatrogenic perforations, since patients are likely to have taken nothing by mouth prior to the procedure, which limits the amount of gastric contents",
"     </li>",
"     <li>",
"      Clinically stable patients who are young and healthy",
"     </li>",
"     <li>",
"      Patients who present within 24 hours of the perforation, or patients with a delayed presentation who are hemodynamically stable without signs of sepsis",
"     </li>",
"     <li>",
"      Cervical esophageal perforations",
"     </li>",
"     <li>",
"      Small transmural thoracic perforations with local, circumscribed extravasation of contrast",
"     </li>",
"     <li>",
"      Absence of continued extravasation into the mediastinum or pleura and emptying of contrast from the perforation site into the distal esophagus and stomach during contrast esophagography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Characteristics associated with poor outcomes include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis, respiratory failure, and shock",
"     </li>",
"     <li>",
"      Intra-abdominal perforations",
"     </li>",
"     <li>",
"      Perforations in multiple locations",
"     </li>",
"     <li>",
"      Large perforations with widespread contamination",
"     </li>",
"     <li>",
"      Perforations involving the pleural cavities",
"     </li>",
"     <li>",
"      Perforations with retained foreign bodies",
"     </li>",
"     <li>",
"      Perforations within neoplastic tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, it is appropriate to consider medical management if all of the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/2,41\">",
"     2,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The perforation is diagnosed early, or if diagnosed late, the leak is contained",
"     </li>",
"     <li>",
"      The leak is contained within the neck or mediastinum or between the mediastinum and visceral lung pleura",
"     </li>",
"     <li>",
"      Contrast is able to flow back into the esophagus from the cavity surrounding the perforation",
"     </li>",
"     <li>",
"      The injury is not in neoplastic tissue, is not in the abdomen, and is not proximal to an obstruction",
"     </li>",
"     <li>",
"      The patient has minimal symptoms",
"     </li>",
"     <li>",
"      Signs and symptoms of sepsis are absent",
"     </li>",
"     <li>",
"      Access to contrast studies can be obtained at any time of day",
"     </li>",
"     <li>",
"      An experienced thoracic surgeon is readily available if the patient deteriorates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not fulfill these criteria should be considered for surgical management. However, in patients who are deemed to be at high-risk for surgical intervention, the risks of surgery need to be weighed against the benefits. In some cases, nonoperative therapy (medical or endoscopic management) may be preferable in such patients. In addition, endoscopic management may be an option for perforations associated with neoplastic tissue. (See",
"    <a class=\"local\" href=\"#H27673437\">",
"     'Endoscopic management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H250904539\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Approach to medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are appropriate candidates for medical management, treatment includes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H150633261\">",
"     'Patient selection for medical management'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of all oral intake for at least 7 days",
"     </li>",
"     <li>",
"      Parenteral nutrition support",
"     </li>",
"     <li>",
"      Intravenous broad spectrum antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      ) for 7 to 14 days",
"     </li>",
"     <li>",
"      Drainage of fluid collections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of a nasogastric tube, which may help minimize extravasation of oral secretions through the perforation, is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/37\">",
"     37",
"    </a>",
"    ]. Some advocate placing a tube above the perforation, others suggest using a tube that crosses the perforation, and others do not use a nasogastric tube at all. However, passage of a tube into the stomach may be dangerous in the setting of a perforation and can lead to the reflux of gastric contents. Because of these risks, we do not place a nasogastric tube for management of esophageal perforation.",
"   </p>",
"   <p>",
"    If the patient is improving clinically, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    esophagram should be obtained after seven days. Management will then depend upon what is seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is no contrast extravasation, clear liquids can be initiated. The diet can then be advanced as tolerated.",
"     </li>",
"     <li>",
"      If the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      esophagram demonstrates that the perforation is still present, but is smaller, then it is reasonable to wait another seven days to allow more time for healing and then repeat the study. At that time, if there is no perforation demonstrated, clear liquids can be initiated and the diet advanced as tolerated. If the perforation is still present after two weeks, we proceed with placement of a removable covered metal stent. (See",
"      <a class=\"local\" href=\"#H27673437\">",
"       'Endoscopic management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the perforation is the same size or larger, then our approach is to place a removable covered metal stent to treat the perforation. (See",
"      <a class=\"local\" href=\"#H27673437\">",
"       'Endoscopic management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who show signs of clinical deterioration during medical management require surgical intervention. Surgery is indicated in patients who are being managed medically if any of the following develop [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H250904539\">",
"     'Surgical management'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A perforation that initially had limited extravasation of contrast develops free diffuse extravasation",
"     </li>",
"     <li>",
"      Extension of the perforation",
"     </li>",
"     <li>",
"      Clinical deterioration, persistent fevers, or sepsis (if a collection that is amenable to percutaneous drainage is present then attempted drainage of the collection prior to proceeding with surgery is reasonable)",
"     </li>",
"     <li>",
"      Progression of pneumomediastinum or pneumothorax",
"     </li>",
"     <li>",
"      Development of an empyema",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154483597\">",
"    <span class=\"h4\">",
"     Outcomes with medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that in appropriately selected patients, medical management can be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 26 patients with iatrogenic perforations who were managed medically, four patients (15 percent) died, and one patient required surgery because of mediastinal soilage and sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/44\">",
"       44",
"      </a>",
"      ]. Of the patients who died, one had presented more than 24 hours after the perforation, two had perforations in the setting of esophageal cancer, and one was elderly with renal failure.",
"     </li>",
"     <li>",
"      In a series of 47 patients with esophageal perforations (25 iatrogenic), all 34 of the patients treated with medical management survived and had documented esophageal healing at the time of discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27673437\">",
"    <span class=\"h3\">",
"     Endoscopic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removable plastic or covered metal esophageal stents now make it possible to treat some patients with esophageal perforations endoscopically. Stents may be appropriate for patients with perforations in the setting of an esophageal neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] or for patients who are unlikely to tolerate more extensive surgery, provided an endoscopist who is experienced with esophageal stent placement is available.",
"   </p>",
"   <p>",
"    Multiple series have described the successful use of stents for esophageal perforations, though no large trials have been carried out [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/47-53\">",
"     47-53",
"    </a>",
"    ]. In one series, 33 patients (19 of whom had an iatrogenic perforation) underwent stenting with removable stents [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/47\">",
"     47",
"    </a>",
"    ]. The stent sealed the lesion in 32 patients (97 percent). Stent extractions were uncomplicated in all 23 patients who had their stents removed within six weeks. Ten patients had their stents removed between 6 and 84 weeks after placement. In that group, there were six extraction-related complications. Ultimately, four patients (12 percent) required an esophageal resection. In three it was due to failed stent therapy, and in one it was due to failed stent removal.",
"   </p>",
"   <p>",
"    If an esophageal stent is used, a repeat esophagram should be obtained in one to two days to document that the perforation has sealed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ]. Once confirmed, the patient may resume oral intake (typically clear liquids to start, with advancement of the diet as tolerated). If stent migration occurs, an attempt to reposition or to replace the stent is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal amount of time to leave the stent in place has not been established. Stents are often removed six to eight weeks following insertion, but the longer the stent is left in place, the more likely that granulation tissue may develop that may make stent removal difficult. There are reports of removal in as few as 10 to 21 days with complete healing of the perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/46,48,49\">",
"     46,48,49",
"    </a>",
"    ]. In patients being treated with a stent, we suggest removal within six weeks of placement.",
"   </p>",
"   <p>",
"    There have also been reports suggesting that endoscopic clips may be used to treat patients who have acute esophageal perforations due to therapeutic endoscopy, provided there is no evidence of significant extraesophageal contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/54-60\">",
"     54-60",
"    </a>",
"    ]. However, until more data become available, we suggest that endoscopic clips only be used to close perforations in the setting of clinical trials by endoscopists who are highly skilled in their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250904539\">",
"    <span class=\"h3\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are not candidates for or who fail conservative attempts at treatment require surgical treatment. This can include primary repair of the defect, resection of the defect, diversion, drainage of collections, or in some cases, esophagectomy. The surgical approach is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/329?source=see_link\">",
"     \"Surgical management of esophageal perforation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154484442\">",
"    <span class=\"h1\">",
"     NONSPECIFIC CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain is sometimes observed following stricture dilation, even in patients without a perforation. This nonspecific chest pain is usually mild, self-limited, and requires no specific therapy. Rare patients require a period of a liquid diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesics. Chest pain following dilation is commonly observed in patients with eosinophilic esophagitis in whom even gentle dilation can cause mucosal tearing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforation. It is also relatively common when dilation is followed by placement of an expandable stent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link\">",
"     \"Expandable stents in the treatment of esophageal obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=see_link&amp;anchor=H209738#H209738\">",
"     \"Treatment of eosinophilic esophagitis\", section on 'Esophageal dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An esophageal perforation should be excluded if the patient's pain is moderate to severe, if it fails to improve after one to two hours, or if there are other symptoms suggestive of a perforation. In addition, patients with post-procedure pain should be given nothing by mouth until it is clear that their pain is improving. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BACTEREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal dilation has the highest incidence of bacteremia of all gastrointestinal endoscopic procedures, occurring in approximately 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/61\">",
"     61",
"    </a>",
"    ]. In spite of this, complications of bacteremia such as endocarditis are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/62\">",
"     62",
"    </a>",
"    ]. A survey performed in 1976 found only two cases of endocarditis in over 23,000 dilations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for antibiotic prophylaxis have been established by the American Society for Gastrointestinal Endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/63\">",
"     63",
"    </a>",
"    ] and the American Heart Association (",
"    <a class=\"graphic graphic_table graphicRef51133 \" href=\"UTD.htm?30/19/31037\">",
"     table 1",
"    </a>",
"    ). The guidelines do not recommend antibiotic prophylaxis for esophageal dilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant hemorrhage related to esophageal dilation is uncommon. In one series, hemorrhage requiring blood transfusions occurred in 0.2 percent of esophageal dilations with mechanical dilators [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/3\">",
"     3",
"    </a>",
"    ]. Another series found significant hemorrhage in 2 percent of patients who underwent balloon dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/64\">",
"     64",
"    </a>",
"    ]. However, subsequent series suggested that the incidence of hemorrhage is infrequent, regardless of the type of dilator used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic evaluation and therapy is not required in a hemodynamically stable patient with a small amount of hematemesis or coffee ground emesis. However, patients with ongoing bleeding, hemodynamic instability, or a drop in hematocrit should undergo endoscopy for evaluation and treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS RELATED TO ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with procedural sedation and the endoscopy itself include aspiration pneumonia, respiratory failure, and cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/57/10137/abstract/3,67\">",
"     3,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=see_link&amp;anchor=H67011650#H67011650\">",
"     \"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major complication of esophageal dilation is esophageal perforation, which is associated with a mortality rate of approximately 20 percent. The incidence of perforation is influenced by the etiology of the stricture, the experience of the endoscopist, and the techniques and equipment used. In general, perforation rates associated with esophageal stricture dilation are low (one to two per thousand). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Esophageal perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of esophageal perforation may include neck, chest, or back pain, hoarseness, dysphagia, odynophagia, dyspnea, hematemesis, subcutaneous emphysema, and symptoms of an acute abdomen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an esophageal perforation is based upon recognition of the clinical features and radiographic evaluation. The diagnosis should be suspected in patients who develop significant neck, chest, or abdominal pain following endoscopy. Generally, the evaluation starts with plain thoracic and cervical X-rays. If needed, contrast esophagography or computed tomographic (CT) scanning may be obtained to confirm the diagnosis or to look for intrathoracic and intra-abdominal collections that require drainage. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with esophageal perforation following esophageal dilation depends upon the severity of the perforation and the elapsed time between the perforation and its diagnosis. Management options include medical management, endoscopic therapy, and surgery. (See",
"      <a class=\"local\" href=\"#H27673362\">",
"       'Management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Regardless of what management approach is chosen, all patients with an esophageal perforation require the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoidance of all oral intake",
"     </li>",
"     <li>",
"      Nutritional support, typically parenteral",
"     </li>",
"     <li>",
"      Intravenous broad spectrum antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intravenous proton pump inhibitor",
"     </li>",
"     <li>",
"      Drainage of fluid",
"      <span class=\"nowrap\">",
"       collections/debridement",
"      </span>",
"      of infected and necrotic tissue if present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest pain is sometimes observed following stricture dilation, even in patients without a perforation. It is usually mild, self-limited, and requires no specific therapy. However, an esophageal perforation should be excluded if the patient's pain is moderate to severe, if it fails to improve after one to two hours, or if there are other symptoms suggestive of a perforation. In addition, patients with post-procedure pain should be given nothing by mouth until it is clear that their pain is improving. (See",
"      <a class=\"local\" href=\"#H154484442\">",
"       'Nonspecific chest pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other uncommon complications of esophageal stricture dilation include bacteremia and hemorrhage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bacteremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/1\">",
"      Standards of Practice Committee, Egan JV, Baron TH, et al. Esophageal dilation. Gastrointest Endosc 2006; 63:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/2\">",
"      Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/3\">",
"      Mandelstam P, Sugawa C, Silvis SE, et al. Complications associated with esophagogastroduodenoscopy and with esophageal dilation. Gastrointest Endosc 1976; 23:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/4\">",
"      Pereira-Lima JC, Ramires RP, Zamin I Jr, et al. Endoscopic dilation of benign esophageal strictures: report on 1043 procedures. Am J Gastroenterol 1999; 94:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/5\">",
"      Hernandez LV, Jacobson JW, Harris MS, Hernandez LJ. Comparison among the perforation rates of Maloney, balloon, and savary dilation of esophageal strictures. Gastrointest Endosc 2000; 51:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/6\">",
"      Piotet E, Escher A, Monnier P. Esophageal and pharyngeal strictures: report on 1,862 endoscopic dilatations using the Savary-Gilliard technique. Eur Arch Otorhinolaryngol 2008; 265:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/7\">",
"      Karnak I, Tanyel FC, B&uuml;y&uuml;kpamuk&ccedil;u N, Hi&ccedil;s&ouml;nmez A. Esophageal perforations encountered during the dilation of caustic esophageal strictures. J Cardiovasc Surg (Torino) 1998; 39:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/8\">",
"      Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA 1976; 235:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/9\">",
"      Nostrant TT, Nandi PS. Esophageal dilation. Gastroenterologist 1998; 6:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/10\">",
"      Marshall JB, Afridi SA, King PD, et al. Esophageal dilation with polyvinyl (American) dilators over a marked guidewire: practice and safety at one center over a 5-yr period. Am J Gastroenterol 1996; 91:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/11\">",
"      Tucker LE. Esophageal stricture: results of dilation of 300 patients. Mo Med 1992; 89:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/12\">",
"      Swaroop VS, Desai DC, Mohandas KM, et al. Dilation of esophageal strictures induced by radiation therapy for cancer of the esophagus. Gastrointest Endosc 1994; 40:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/13\">",
"      Kaplan M, Mutlu EA, Jakate S, et al. Endoscopy in eosinophilic esophagitis: \"feline\" esophagus and perforation risk. Clin Gastroenterol Hepatol 2003; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/14\">",
"      Jung KW, Gundersen N, Kopacova J, et al. Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis. Gastrointest Endosc 2011; 73:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/15\">",
"      Cohen MS, Kaufman AB, Palazzo JP, et al. An audit of endoscopic complications in adult eosinophilic esophagitis. Clin Gastroenterol Hepatol 2007; 5:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/16\">",
"      Eisenbach C, Merle U, Schirmacher P, et al. Perforation of the esophagus after dilation treatment for dysphagia in a patient with eosinophilic esophagitis. Endoscopy 2006; 38 Suppl 2:E43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/17\">",
"      Jacobs JW Jr, Spechler SJ. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci 2010; 55:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/18\">",
"      Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010; 105:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/19\">",
"      Kavic SM, Basson MD. Complications of endoscopy. Am J Surg 2001; 181:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/20\">",
"      S&oslash;reide JA, Viste A. Esophageal perforation: diagnostic work-up and clinical decision-making in the first 24 hours. Scand J Trauma Resusc Emerg Med 2011; 19:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/21\">",
"      Attar S, Hankins JR, Suter CM, et al. Esophageal perforation: a therapeutic challenge. Ann Thorac Surg 1990; 50:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/22\">",
"      Maher MM, Lucey BC, Boland G, et al. The role of interventional radiology in the treatment of mediastinal collections caused by esophageal anastomotic leaks. AJR Am J Roentgenol 2002; 178:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/23\">",
"      Holm AN, de la Mora Levy JG, Gostout CJ, et al. Self-expanding plastic stents in treatment of benign esophageal conditions. Gastrointest Endosc 2008; 67:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/24\">",
"      Dua KS, Vleggaar FP, Santharam R, Siersema PD. Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol 2008; 103:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/25\">",
"      Kim JH, Song HY, Choi EK, et al. Temporary metallic stent placement in the treatment of refractory benign esophageal strictures: results and factors associated with outcome in 55 patients. Eur Radiol 2009; 19:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/26\">",
"      White RK, Morris DM. Diagnosis and management of esophageal perforations. Am Surg 1992; 58:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/27\">",
"      Reeder LB, DeFilippi VJ, Ferguson MK. Current results of therapy for esophageal perforation. Am J Surg 1995; 169:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/28\">",
"      Sawyer R, Phillips C, Vakil N. Short- and long-term outcome of esophageal perforation. Gastrointest Endosc 1995; 41:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/29\">",
"      Sarr MG, Pemberton JH, Payne WS. Management of instrumental perforations of the esophagus. J Thorac Cardiovasc Surg 1982; 84:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/30\">",
"      Han SY, McElvein RB, Aldrete JS, Tishler JM. Perforation of the esophagus: correlation of site and cause with plain film findings. AJR Am J Roentgenol 1985; 145:537.",
"     </a>",
"    </li>",
"    <li>",
"     Peter P Lopez. Complications of esophageal surgery and trauma. In: Complications in srugery and trauma, Stephen M. Cohn.  (Ed), Informa Healthcare USA, Inc., New York 2007. p.257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/32\">",
"      Foley MJ, Ghahremani GG, Rogers LF. Reappraisal of contrast media used to detect upper gastrointestinal perforations: comparison of ionic water-soluble media with barium sulfate. Radiology 1982; 144:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/33\">",
"      Bladergroen MR, Lowe JE, Postlethwait RW. Diagnosis and recommended management of esophageal perforation and rupture. Ann Thorac Surg 1986; 42:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/34\">",
"      Dodds WJ, Stewart ET, Vlymen WJ. Appropriate contrast media for evaluation of esophageal disruption. Radiology 1982; 144:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/35\">",
"      White CS, Templeton PA, Attar S. Esophageal perforation: CT findings. AJR Am J Roentgenol 1993; 160:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/36\">",
"      Madanick RD. Medical management of iatrogenic esophageal perforations. Curr Treat Options Gastroenterol 2008; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/37\">",
"      Shaffer HA Jr, Valenzuela G, Mittal RK. Esophageal perforation. A reassessment of the criteria for choosing medical or surgical therapy. Arch Intern Med 1992; 152:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/38\">",
"      Mengoli LR, Klassen KP. Conservative management of esophageal perforation. Arch Surg 1965; 91:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/39\">",
"      Lyons WS, Seremetis MG, deGuzman VC, Peabody JW Jr. Ruptures and perforations of the esophagus: the case for conservative supportive management. Ann Thorac Surg 1978; 25:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/40\">",
"      Cameron JL, Kieffer RF, Hendrix TR, et al. Selective nonoperative management of contained intrathoracic esophageal disruptions. Ann Thorac Surg 1979; 27:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/41\">",
"      Altorjay A, Kiss J, V&ouml;r&ouml;s A, Boh&aacute;k A. Nonoperative management of esophageal perforations. Is it justified? Ann Surg 1997; 225:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/42\">",
"      Martinez L, Rivas S, Hern&aacute;ndez F, et al. Aggressive conservative treatment of esophageal perforations in children. J Pediatr Surg 2003; 38:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/43\">",
"      Vogel SB, Rout WR, Martin TD, Abbitt PL. Esophageal perforation in adults: aggressive, conservative treatment lowers morbidity and mortality. Ann Surg 2005; 241:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/44\">",
"      Hasan S, Jilaihawi AN, Prakash D. Conservative management of iatrogenic oesophageal perforations--a viable option. Eur J Cardiothorac Surg 2005; 28:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/45\">",
"      White RE, Mungatana C, Topazian M. Expandable stents for iatrogenic perforation of esophageal malignancies. J Gastrointest Surg 2003; 7:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/46\">",
"      Johnsson E, Lundell L, Liedman B. Sealing of esophageal perforation or ruptures with expandable metallic stents: a prospective controlled study on treatment efficacy and limitations. Dis Esophagus 2005; 18:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/47\">",
"      van Heel NC, Haringsma J, Spaander MC, et al. Short-term esophageal stenting in the management of benign perforations. Am J Gastroenterol 2010; 105:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/48\">",
"      Fischer A, Thomusch O, Benz S, et al. Nonoperative treatment of 15 benign esophageal perforations with self-expandable covered metal stents. Ann Thorac Surg 2006; 81:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/49\">",
"      Freeman RK, Van Woerkom JM, Ascioti AJ. Esophageal stent placement for the treatment of iatrogenic intrathoracic esophageal perforation. Ann Thorac Surg 2007; 83:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/50\">",
"      Salminen P, Gullichsen R, Laine S. Use of self-expandable metal stents for the treatment of esophageal perforations and anastomotic leaks. Surg Endosc 2009; 23:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/51\">",
"      Schmidt SC, Strauch S, R&ouml;sch T, et al. Management of esophageal perforations. Surg Endosc 2010; 24:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/52\">",
"      Kiev J, Amendola M, Bouhaidar D, et al. A management algorithm for esophageal perforation. Am J Surg 2007; 194:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/53\">",
"      Leers JM, Vivaldi C, Sch&auml;fer H, et al. Endoscopic therapy for esophageal perforation or anastomotic leak with a self-expandable metallic stent. Surg Endosc 2009; 23:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/54\">",
"      Qadeer MA, Dumot JA, Vargo JJ, et al. Endoscopic clips for closing esophageal perforations: case report and pooled analysis. Gastrointest Endosc 2007; 66:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/55\">",
"      Raju GS, Thompson C, Zwischenberger JB. Emerging endoscopic options in the management of esophageal leaks (videos). Gastrointest Endosc 2005; 62:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/56\">",
"      Wewalka FW, Clodi PH, Haidinger D. Endoscopic clipping of esophageal perforation after pneumatic dilation for achalasia. Endoscopy 1995; 27:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/57\">",
"      Cipolletta L, Bianco MA, Rotondano G, et al. Endoscopic clipping of perforation following pneumatic dilation of esophagojejunal anastomotic strictures. Endoscopy 2000; 32:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/58\">",
"      Abe N, Sugiyama M, Hashimoto Y, et al. Endoscopic nasomediastinal drainage followed by clip application for treatment of delayed esophageal perforation with mediastinitis. Gastrointest Endosc 2001; 54:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/59\">",
"      Shimizu Y, Kato M, Yamamoto J, et al. Endoscopic clip application for closure of esophageal perforations caused by EMR. Gastrointest Endosc 2004; 60:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/60\">",
"      Gerke H, Crowe GC, Iannettoni MD. Endoscopic closure of cervical esophageal perforation caused by traumatic insertion of a mucosectomy cap. Ann Thorac Surg 2007; 84:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/61\">",
"      Botoman VA, Surawicz CM. Bacteremia with gastrointestinal endoscopic procedures. Gastrointest Endosc 1986; 32:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/62\">",
"      Niv Y, Bat L, Motro M. Bacterial endocarditis after Hurst bougienage in a patient with a benign esophageal stricture and mitral valve prolapse. Gastrointest Endosc 1985; 31:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/63\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopy. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1995; 42:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/64\">",
"      Kozarek RA. Hydrostatic balloon dilation of gastrointestinal stenoses: a national survey. Gastrointest Endosc 1986; 32:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/65\">",
"      Shemesh E, Czerniak A. Comparison between Savary-Gilliard and balloon dilatation of benign esophageal strictures. World J Surg 1990; 14:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/66\">",
"      Saeed ZA, Winchester CB, Ferro PS, et al. Prospective randomized comparison of polyvinyl bougies and through-the-scope balloons for dilation of peptic strictures of the esophagus. Gastrointest Endosc 1995; 41:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/57/10137/abstract/67\">",
"      Lanza FL, Graham DY. Bougienage is effective therapy for most benign esophageal strictures. JAMA 1978; 240:844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2275 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10137=[""].join("\n");
var outline_f9_57_10137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESOPHAGEAL PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154482667\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150633334\">",
"      - Thoracic and cervical x-rays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150633349\">",
"      - Contrast esophagography (Gastrografin or barium swallow)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150633364\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154482778\">",
"      - Flexible upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27673362\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154482785\">",
"      - General management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H150633261\">",
"      Patient selection for medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Approach to medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154483597\">",
"      Outcomes with medical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27673437\">",
"      - Endoscopic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H250904539\">",
"      - Surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154484442\">",
"      NONSPECIFIC CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BACTEREMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS RELATED TO ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2275|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/2/32814\" title=\"diagnostic image 1\">",
"      Esophageal perforation UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/19/31037\" title=\"table 1\">",
"      ASGE guidelines Abx prophylxs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29606?source=related_link\">",
"      Boerhaave's syndrome: Effort rupture of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/48/32518?source=related_link\">",
"      Management of non-iatrogenic traumatic esophageal perforations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=related_link\">",
"      Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=related_link\">",
"      Pneumatic dilation and botulinum toxin injection for achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/329?source=related_link\">",
"      Surgical management of esophageal perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_57_10138="Clarithromycin: Drug information";
var content_f9_57_10138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clarithromycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=see_link\">",
"    see \"Clarithromycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"    see \"Clarithromycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Biaxin&reg;;",
"     </li>",
"     <li>",
"      Biaxin&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clarithromycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Clarithromycin;",
"     </li>",
"     <li>",
"      Biaxin&reg;;",
"     </li>",
"     <li>",
"      Biaxin&reg; XL;",
"     </li>",
"     <li>",
"      Dom-Clarithromycin;",
"     </li>",
"     <li>",
"      Mylan-Clarithromycin;",
"     </li>",
"     <li>",
"      PMS-Clarithromycin;",
"     </li>",
"     <li>",
"      RAN&trade;-Clarithromycin;",
"     </li>",
"     <li>",
"      ratio-Clarithromycin;",
"     </li>",
"     <li>",
"      Riva-Clarithromycin;",
"     </li>",
"     <li>",
"      Sandoz-Clarithromycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Macrolide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Oral: 250-500 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute exacerbation of chronic bronchitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     : 250 mg every 12 hours for 7-14 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      H. influenzae",
"     </i>",
"     : 500 mg every 12 hours for 7-14 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      H. parainfluenzae",
"     </i>",
"     : 500 mg every 12 hours for 7 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute maxillary sinusitis:",
"     </b>",
"     Oral: 500 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mycobacterial infection (prevention and treatment):",
"     </b>",
"     Oral: 500 mg twice daily (use with other antimycobacterial drugs, eg, ethambutol or rifampin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peptic ulcer disease:",
"     </b>",
"     Eradication of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     : Dual or triple combination regimens with bismuth subsalicylate, amoxicillin, an H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist, or proton-pump inhibitor: 500 mg every 8-12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pertussis (unlabeled use; CDC, 2005):",
"     </b>",
"     Oral: 500 mg twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis, tonsillitis:",
"     </b>",
"     Oral: 250 mg every 12 hours for 10 days.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      C. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      M. pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     : 250 mg every 12 hours for 7-14 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      H. influenzae",
"     </i>",
"     : 250 mg every 12 hours for 7 days",
"     <b>",
"      or",
"     </b>",
"     1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      H. parainfluenzae",
"     </i>",
"     and",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     : 1000 mg (two 500 mg extended release tablets) once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"     Oral: 500 mg 30-60 minutes prior to procedure.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infection, uncomplicated:",
"     </b>",
"     Oral: 250 mg every 12 hours for 7-14 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F152399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"      see \"Clarithromycin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     Oral: Infants &gt;3 months and Children:",
"     <b>",
"      Note:",
"     </b>",
"     A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Presumed atypical",
"     <i>",
"      (M. pneumoniae, C. pneumoniae, C. trachomatis)",
"     </i>",
"     infection, mild-to-severe atypical infection or step-down therapy (alternative to azithromycin): 7.5 mg/kg/dose (maximum: 1000 mg) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mycobacterial infection (prevention and treatment):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's recommendation: 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Safety of clarithromycin for MAC not studied in children &lt;20 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HIV-exposed/-positive (unlabeled use; CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Primary prophylaxis:",
"     </i>",
"     7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Secondary prophylaxis:",
"     </i>",
"     7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily,  plus ethambutol, with or without rifabutin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     7.5-15 mg/kg/dose (maximum: 500 mg/dose) twice daily plus ethambutol, plus rifabutin (for severe disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pertussis (unlabeled use; CDC, 2005):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-5 months: 7.5 mg/kg/dose every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 months: 7.5 mg/kg/dose every 12 hours for 7 days (maximum: 1000 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis, group A streptococci in penicillin-allergic patients (IDSA guidelines):",
"     </b>",
"     Oral: 7.5 mg/kg/dose every 12 hours (maximum: 500 mg daily) for 10 days (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"     Oral: 15 mg/kg 30-60 minutes before procedure (maximum: 500 mg).",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sinusitis, bronchitis, skin infections:",
"     </b>",
"     Oral: 7.5 mg/kg/dose every 12 hours for 10 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F152379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Decrease clarithromycin dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis:  Administer after HD session is completed (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In combination with atazanavir or ritonavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Decrease clarithromycin  dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Decrease clarithromycin dose by 75%.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F152380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosing adjustment is needed as long as renal function is normal.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral: 125 mg/5 mL (50 mL, 100 mL); 250 mg/5 mL (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biaxin&reg;: 125 mg/5 mL (50 mL, 100 mL); 250 mg/5 mL (50 mL, 100 mL) [fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biaxin&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biaxin&reg; XL: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clarithromycin immediate release tablets and oral suspension may be administered with or without meals. Give every 12 hours rather than twice daily to avoid peak and trough variation. Shake suspension well before each use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Extended release tablets: Should be given with food. Do not crush or chew extended release tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute maxillary sinusitis due to susceptible",
"     <i>",
"      H. influenzae, S. pneumoniae,",
"     </i>",
"     or",
"     <i>",
"      Moraxella catarrhalis",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute otitis media due to susceptible",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Community-acquired pneumonia due to susceptible",
"     <i>",
"      Mycoplasma pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     , or",
"     <i>",
"      Chlamydia pneumoniae",
"     </i>",
"     (TWAR)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Disseminated mycobacterial infections due to",
"     <i>",
"      M. avium",
"     </i>",
"     or",
"     <i>",
"      M. intracellulare",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pharyngitis/tonsillitis due to susceptible",
"     <i>",
"      S. pyogenes",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of disseminated mycobacterial infections due to MAC disease in patients with advanced HIV infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uncomplicated skin/skin structure infection due to susceptible",
"     <i>",
"      S. aureus, S. pyogenes,",
"     </i>",
"     or mycobacterial infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pharyngitis/tonsillitis due to susceptible",
"     <i>",
"      S. pyogenes",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute maxillary sinusitis due to susceptible",
"     <i>",
"      H. influenzae, M. catarrhalis,",
"     </i>",
"     or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute exacerbation of chronic bronchitis due to susceptible",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      H. parainfluenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     , or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Community-acquired pneumonia due to susceptible",
"     <i>",
"      H. influenzae, H. parainfluenzae, M. catarrhalis, Mycoplasma pneumoniae, S. pneumoniae,",
"     </i>",
"     or",
"     <i>",
"      Chlamydia pneumoniae",
"     </i>",
"     (TWAR)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uncomplicated skin/skin structure infections due to susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Disseminated mycobacterial infections due to",
"     <i>",
"      M. avium",
"     </i>",
"     or",
"     <i>",
"      M. intracellulare",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of disseminated mycobacterial infections due to",
"     <i>",
"      M. avium",
"     </i>",
"     complex (MAC) disease (eg, patients with advanced HIV infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duodenal ulcer disease due to",
"     <i>",
"      H. pylori",
"     </i>",
"     in regimens with other drugs including amoxicillin and lansoprazole or  omeprazole, or in combination with omeprazole or ranitidine bismuth citrate (no longer marketed in the U.S.).",
"     <b>",
"      Note:",
"     </b>",
"     Regimens that contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2154503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pertussis (CDC guidelines); alternate antibiotic for prophylaxis of infective endocarditis in patients who are allergic to penicillin and undergoing dental procedures (ACC/AHA guidelines)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clarithromycin may be confused with Claritin&reg;, clindamycin, erythromycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste (adults 3% to 7%), diarrhea (adults 3% to 6%; children 6%), vomiting (children 6%), nausea (adults 3%), abdominal pain (adults 2%; children 3%), dyspepsia (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Prothrombin time increased (adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening):  Alkaline phosphatase increased, ALT increased, anaphylaxis, anorexia, anxiety, AST increased, behavioral changes, bilirubin increased, cholestatic hepatitis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     colitis, confusion, depersonalization, depression, disorientation, dizziness, drug rash with eosinophilia and systemic symptoms (DRESS),  GGT increased, glossitis, hallucinations, hearing loss (reversible), hemorrhage, Henoch-Sch&ouml;nlein purpura, hepatic dysfunction, hepatic failure, hepatitis, hypoglycemia, insomnia, interstitial nephritis, jaundice, leukopenia, LDH increased, manic behavior, myalgia, neutropenia, nightmares, oral moniliasis, pancreatitis, psychosis, QT prolongation, rhabdomyolysis, seizure, serum creatinine increased, smell loss, Stevens-Johnson syndrome, stomatitis, taste loss, thrombocytopenia, tinnitus, tongue discoloration, tooth discoloration (reversible with dental cleaning), torsade de pointes, toxic epidermal necrolysis, tremor, urticaria, ventricular tachycardia, ventricular arrhythmia, vertigo, white blood cell count decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic; use with ergot derivatives, pimozide, cisapride, astemizole, terfenadine, colchicine (if patient has concomitant renal or hepatic impairment), lovastatin, simvastatin; history of cholestatic jaundice or hepatic dysfunction with prior clarithromycin use; history of QT prolongation or ventricular arrhythmia, including torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Macrolides have been associated with rare QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization; avoid use in patients with uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and patients receiving Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe acute reactions have (rarely) been reported, including anaphylaxis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), and Henoch-Sch&ouml;nlein purpura; discontinue therapy immediately and urgently initiate treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease (CAD): Use with caution in patients with CAD; postmarketing safety trial suggests increased risk of cardiovascular mortality with short-term clarithromycin use (vs placebo) in patients with stable CAD. However, more smokers were randomized to the clarithromycin arm (Jespersen, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Elevated liver function tests and hepatitis (hepatocellular, cholestatic) have been reported; usually reversible after discontinuation of clarithromycin.  May lead to hepatic failure or death (rarely), especially in the presence of pre-existing hepatic disease or concomitant use of hepatotoxic medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms and new onset of symptoms has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage adjustment required with severe renal impairment; decreased dosage or prolonged dosing interval may be appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colchicine: Colchicine toxicity (including fatalities) has been reported with concomitant use; reduction of colchicine dose is recommended if coadministration is necessary. Use caution in the elderly; concomitant use is contraindicated in patients with renal or hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major inhibitor of CYP3A4: Use caution with any agents with substantial metabolism through the CYP3A4 pathway; high potential for drug interactions exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be at increased risk of torsade de pointes, particularly if concurrent renal/hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release formulation: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10-14 days of therapy (triple or quadruple) for eradication of",
"     <i>",
"      H. pylori",
"     </i>",
"     (Chey, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F152413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Clarithromycin may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin.  Management: In patients with an estimated creatinine clearance of 50 to 60 mL/min, the clarithromycin dose needs to be reduced by 50% when used together with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Clarithromycin may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Clarithromycin may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlipiZIDE: Clarithromycin may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: Clarithromycin may increase the serum concentration of GlyBURIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed. Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Clarithromycin may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Clarithromycin may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Clarithromycin may increase the serum concentration of Vardenafil.  Management: Recommendations regarding the concomitant use of vardenafil with clarithromycin vary between international labelings and between commercially available vardenafil brand name products (Levitra, Staxyn). Consult appropriate product labelings.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.  Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F152368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Immediate release: Food delays rate, but not extent of absorption; Extended release: Food increases clarithromycin AUC by ~30% relative to fasting conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease clarithromycin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse fetal effects have been documented in some animal reproduction studies. Clarithromycin crosses the placenta. The manufacturer recommends that clarithromycin not be used in a pregnant woman unless there are no alternative therapies. An increased risk of teratogenic events has not been observed following maternal use of clarithromycin.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F152356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if clarithromycin is excreted in human breast milk. The manufacturer recommends that caution be exercised when administering clarithromycin to breast-feeding women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other macrolides are considered compatible with breast-feeding and clarithromycin is used therapeutically in infants. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F152357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clarithromycin immediate release tablets and oral suspension may be given with or without meals, and may be taken with milk. Extended release tablets should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F152354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Biaxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (50 mL): $71.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Clarithromycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (50 mL): $28.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (50 mL): $53.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Biaxin XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $518.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Biaxin XL Pac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (14): $119.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Clarithromycin ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $300.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Biaxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (60): $484.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $484.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Clarithromycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (60): $360.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $360.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6699915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, BUN, creatinine; perform culture and sensitivity studies prior to initiating drug therapy as appropriate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F152358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abbotic (ID);",
"     </li>",
"     <li>",
"      Abbotic XL (ID);",
"     </li>",
"     <li>",
"      Adel (MX);",
"     </li>",
"     <li>",
"      Aeroxina (AR);",
"     </li>",
"     <li>",
"      Avexus (MY);",
"     </li>",
"     <li>",
"      Bacterfin (EC);",
"     </li>",
"     <li>",
"      Biaxin HP (DE);",
"     </li>",
"     <li>",
"      Biclar (BE, LU);",
"     </li>",
"     <li>",
"      Bicrolid (ID, SG);",
"     </li>",
"     <li>",
"      Binoclar (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bysclas (PH);",
"     </li>",
"     <li>",
"      C-Clarin (KP);",
"     </li>",
"     <li>",
"      Carimycin (TW);",
"     </li>",
"     <li>",
"      Ciracle (KP);",
"     </li>",
"     <li>",
"      Clabet (PH);",
"     </li>",
"     <li>",
"      Clacina (TH);",
"     </li>",
"     <li>",
"      Clamycin (PH);",
"     </li>",
"     <li>",
"      Clarac (AU, NZ);",
"     </li>",
"     <li>",
"      Claranta (PH);",
"     </li>",
"     <li>",
"      Clari (KP, SG);",
"     </li>",
"     <li>",
"      Claribid (IN);",
"     </li>",
"     <li>",
"      Claridar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Clarihexal (AU);",
"     </li>",
"     <li>",
"      Clarimac (IN);",
"     </li>",
"     <li>",
"      Clarimax (CN);",
"     </li>",
"     <li>",
"      Clarimed (PE);",
"     </li>",
"     <li>",
"      Claripen (SG);",
"     </li>",
"     <li>",
"      Clariston (EC);",
"     </li>",
"     <li>",
"      Claritab (BR);",
"     </li>",
"     <li>",
"      Clarith (JP, TH);",
"     </li>",
"     <li>",
"      Clariwin (SG);",
"     </li>",
"     <li>",
"      Clarix (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Claroma (KP);",
"     </li>",
"     <li>",
"      Claron (TH);",
"     </li>",
"     <li>",
"      Clarosin (KP);",
"     </li>",
"     <li>",
"      Clasine (PE);",
"     </li>",
"     <li>",
"      Claxin (KP);",
"     </li>",
"     <li>",
"      Cleron (SG);",
"     </li>",
"     <li>",
"      Clormicin (CO);",
"     </li>",
"     <li>",
"      Crixan OD (PH);",
"     </li>",
"     <li>",
"      Fascar (TH);",
"     </li>",
"     <li>",
"      Gervaken (MX);",
"     </li>",
"     <li>",
"      Heliclar (LU);",
"     </li>",
"     <li>",
"      Heliclo (KP);",
"     </li>",
"     <li>",
"      Kalixocin (AU);",
"     </li>",
"     <li>",
"      Klacid (AE, AT, AU, BG, BH, CH, CL, CR, CY, CZ, DE, DK, EE, EG, ES, FI, GT, HK, HN, HU, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LY, MY, NI, NO, NZ, OM, PA, PL, PT, QA, RU, SA, SE, SG, SV, SY, TH, TR, YE);",
"     </li>",
"     <li>",
"      Klacid MR (MY);",
"     </li>",
"     <li>",
"      Klacid XL (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Klaribac (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Klaricid (AR, BB, BM, BR, BS, BZ, CN, CO, EC, GB, GR, GY, JM, KP, MX, NL, PE, PH, PK, PR, PY, SR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Klaricid Pediatric (PH);",
"     </li>",
"     <li>",
"      Klaricid XL (KP);",
"     </li>",
"     <li>",
"      Klarid (PH);",
"     </li>",
"     <li>",
"      Klaridex (IL);",
"     </li>",
"     <li>",
"      Klarin (IL);",
"     </li>",
"     <li>",
"      Klaris (KP);",
"     </li>",
"     <li>",
"      Klarith (TW);",
"     </li>",
"     <li>",
"      Klarithan (ZA);",
"     </li>",
"     <li>",
"      Klarmyn (MX, PH);",
"     </li>",
"     <li>",
"      Klerimed (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Klerimid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Krobicin (MX);",
"     </li>",
"     <li>",
"      Larith (KP);",
"     </li>",
"     <li>",
"      Limaclo (KP);",
"     </li>",
"     <li>",
"      Macladin (IT);",
"     </li>",
"     <li>",
"      Maclar (LU);",
"     </li>",
"     <li>",
"      Macrodin (PH);",
"     </li>",
"     <li>",
"      Mavid (DE);",
"     </li>",
"     <li>",
"      Maxpectra (MY);",
"     </li>",
"     <li>",
"      Monoclarium (SG);",
"     </li>",
"     <li>",
"      Mononaxy (FR);",
"     </li>",
"     <li>",
"      Naxy (FR);",
"     </li>",
"     <li>",
"      Neo-Clarosip (MX);",
"     </li>",
"     <li>",
"      Onexid (PH);",
"     </li>",
"     <li>",
"      Orixal (ID);",
"     </li>",
"     <li>",
"      Rolicytin (MX);",
"     </li>",
"     <li>",
"      Synclar (HK);",
"     </li>",
"     <li>",
"      Veclam (IT);",
"     </li>",
"     <li>",
"      Zeclar (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exerts its antibacterial action by binding to 50S ribosomal subunit resulting in inhibition of protein synthesis. The 14-OH metabolite of clarithromycin is twice as active as the parent compound against certain organisms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release: Rapid; food delays rate, but not extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely into most body tissues except CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 42% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic via CYP3A4; converted to 14-OH clarithromycin (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: Clarithromycin: 3-7 hours; 14-OH-clarithromycin: 5-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak:  Immediate release: 2-3 hours; Extended release: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (20% to 40% as unchanged drug; additional 10% to 15% as metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Approximates normal GFR",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, &ldquo;Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1993, 148(5):1418-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8239186/pubmed\" id=\"8239186\" target=\"_blank\">",
"        8239186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aspin MM, Hoberman A, McCarty J, et al, &ldquo;Comparative Study of the Safety and Efficacy of Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Acute Otitis Media in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(1):136-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8021763/pubmed\" id=\"8021763\" target=\"_blank\">",
"        8021763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barradell LB, Plosker GL, and McTavish D, &ldquo;Clarithromycin. A Review of Its Pharmacological Properties and Therapeutic Use in",
"      <i>",
"       Mycobacterium avium-intracellulare",
"      </i>",
"      Complex Infection in Patients With Acquired Immune Deficiency Syndrome,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(2):289-312.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/7691518/pubmed\" id=\"7691518\" target=\"_blank\">",
"        7691518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonow RO, Carabello B, de Leon Jr, AC, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1998, 32(5):1486-1588.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/9809971/pubmed\" id=\"9809971\" target=\"_blank\">",
"        9809971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chu SY, Wilson DS, Guay DR, et al, &ldquo;Clarithromycin Pharmacokinetics in Healthy Young and Elderly Volunteers,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1992, 32(11):1045-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/1474166/pubmed\" id=\"1474166\" target=\"_blank\">",
"        1474166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      1997, 277(22):1794-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/9178793/pubmed\" id=\"9178793\" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldman MP and Longworth DL, &ldquo;The Role of Azithromycin and Clarithromycin in Clinical Practice,&rdquo;",
"      <i>",
"       Cleve Clin J Med",
"      </i>",
"      , 1993, 60(5):359-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8403355/pubmed\" id=\"8403355\" target=\"_blank\">",
"        8403355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Pharmacokinetics of New Macrolides,&rdquo;",
"      <i>",
"       Infect Med",
"      </i>",
"      , 1992, 9(Suppl A):9-13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR and Craft JC, &ldquo;Overview of the Pharmacology of Clarithromycin Suspension in Children and a Comparison With That in Adults,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1993, 12(12 Suppl 3):106-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8295810/pubmed\" id=\"8295810\" target=\"_blank\">",
"        8295810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Husson RN, Ross LA, Sandelli S, et al, &ldquo;Orally Administered Clarithromycin for the Treatment of Systemic",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Infection in Children With Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 124(5 Pt 1):807-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8176574/pubmed\" id=\"8176574\" target=\"_blank\">",
"        8176574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jespersen CM, Als-Nielsen B, Damgaard M, et al, &ldquo;Randomised Placebo Controlled Multicentre Trial to Assess Short Term Clarithromycin for Patients with Stable Coronary Heart Disease: CLARICOR Trial,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7532):22-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/16339220/pubmed\" id=\"16339220\" target=\"_blank\">",
"        16339220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langtry HD and Brogden RN, &ldquo;Clarithromycin. A Review of Its Efficacy in the Treatment of Respiratory Tract Infections in Immunocompetent Patients,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(6):973-1004.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/9179528/pubmed\" id=\"9179528\" target=\"_blank\">",
"        9179528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McConnell SA and Amsden GW, &ldquo;Review and Comparison of Advanced-Generation Macrolides Clarithromycin and Dirithromycin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(4):404-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/10212011/pubmed\" id=\"10212011\" target=\"_blank\">",
"        10212011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nightingale SD, Koster FT, Mertz GJ, et al, &ldquo;Clarithromycin-Induced Mania in Two Patients With AIDS,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 20(6):1563-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/7548513/pubmed\" id=\"7548513\" target=\"_blank\">",
"        7548513",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oteo JA, Gomez-Cadinanos RA, Rosel L, et al, &ldquo;Clarithromycin-Induced Thrombocytopenic Purpura,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1994, 19(6):1170-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/7888564/pubmed\" id=\"7888564\" target=\"_blank\">",
"        7888564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peters DH and Clissold SP, &ldquo;Clarithromycin: A Review of its Antimicrobial Activity, Pharmacokinetic Properties, and Therapeutic Potential,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 44(1):117-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/1379907/pubmed\" id=\"1379907\" target=\"_blank\">",
"        1379907",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Pimozide (Orap) Contraindicated With Clarithromycin (Biaxin) and Other Macrolide Antibiotics,&rdquo;",
"      <i>",
"       FDA Medical Bulletin",
"      </i>",
"      , October 1996, 3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollak PT, Sketris IS, MacKenzie SL, et al, &ldquo;Delirium Probably Induced by Clarithromycin in a Patient Receiving Fluoxetine,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):486-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/7655131/pubmed\" id=\"7655131\" target=\"_blank\">",
"        7655131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Public Health Service Task Force on Prophylaxis and Therapy for",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex, &ldquo;Recommendations on Prophylaxis and Therapy for Disseminated",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Disease in Patients Infected With the Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(12):898-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8395019/pubmed\" id=\"8395019\" target=\"_blank\">",
"        8395019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stafstrom CE, Nohria V, Loganbill H, et al, &ldquo;Erythromycin-induced Carbamazepine Toxicity: A Continuing Problem,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 1995, 149(1):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/7827672/pubmed\" id=\"7827672\" target=\"_blank\">",
"        7827672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tartaglione TA, &ldquo;Therapeutic Options for the Management and Prevention of",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Infection in Patients With the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1996, 16(2):171-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8820462/pubmed\" id=\"8820462\" target=\"_blank\">",
"        8820462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teare JP, Booth JC, Brown JL, et al, &ldquo;Pseudomembranous Colitis Following Clarithromycin Therapy,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 1995, 7(3):275-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/7743311/pubmed\" id=\"7743311\" target=\"_blank\">",
"        7743311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiwari T, Murphy TV, and Moran J, &ldquo;Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-14):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/16340941/pubmed\" id=\"16340941\" target=\"_blank\">",
"        16340941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace RJ Jr, Brown BA, and Griffith DE, &ldquo;Drug Intolerance to High-Dose Clarithromycin Among Elderly Patients,&rdquo;",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 1993, 16(3):215-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/8477575/pubmed\" id=\"8477575\" target=\"_blank\">",
"        8477575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/57/10138/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9273 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10138=[""].join("\n");
var outline_f9_57_10138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152372\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152373\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152420\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152377\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152399\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152378\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152379\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152380\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152345\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152331\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152349\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152348\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2154503\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152427\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152418\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152352\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152335\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152413\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152340\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152368\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152342\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152355\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152384\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152356\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152357\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152354\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699915\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152358\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152334\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152351\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9273\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9273|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=related_link\">",
"      Clarithromycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=related_link\">",
"      Clarithromycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_57_10139="Constrictive bronchiolitis";
var content_f9_57_10139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with the histologic finding of constrictive bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inhalation of dusts or toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mineral dusts - asbestos, silica, iron oxide,",
"aluminum oxide, talc, mica, and coal NO2, sulfur dioxide, ammonia,",
"chlorine, phosgene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection - viral, mycoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connective tissue disease, especially rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic rejection in heart-lung, lung, and bone marrow transplant recipients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Myers, JL, Colby, TV, Clin Chest Med 1993; 14:611.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10139=[""].join("\n");
var outline_f9_57_10139=null;
var title_f9_57_10140="Oral antibiotics for infections due to MRSA";
var content_f9_57_10140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Options for oral treatment of methicillin-resistant Staphylococcus aureus (MRSA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dose (children &gt;28 days)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        300 to 450 mg orally three times daily",
"       </td>",
"       <td>",
"        40 mg/kg per day orally divided in three or four doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        1 DS tab orally twice daily",
"       </td>",
"       <td>",
"        8 to 12 mg trimethoprim component/kg per day orally divided in two doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg orally twice daily",
"       </td>",
"       <td>",
"        <p>",
"         &le;45 kg: 4 mg/kg per day orally divided in two doses",
"        </p>",
"        <p>",
"         &gt;45 kg: 100 mg orally twice daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        200 mg orally once, then 100 mg orally twice daily",
"       </td>",
"       <td>",
"        4 mg/kg orally once, then 4 mg/kg per day divided in two doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        600 mg orally twice daily",
"       </td>",
"       <td>",
"        <p>",
"         &lt;12 years: 30 mg/kg per day orally divided in three doses",
"        </p>",
"        <p>",
"         &ge;12 years: 600 mg orally twice daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Tedizolid",
"       </td>",
"       <td>",
"        &nbsp;200 mg orrally once daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DS: double strength.",
"     <br/>",
"     * Dosing for neonates is provided separately. (See table \"Treatment of cellulitis in neonates.\")",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not recommended for children &lt;8 years of age.",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infect Dis 2011; 52:e18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10140=[""].join("\n");
var outline_f9_57_10140=null;
var title_f9_57_10141="Genital piercings";
var content_f9_57_10141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genital and nipple piercing in males and females*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Healing time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Vertical pin through the glans (Apadravya)",
"        </p>",
"        <p>",
"         Horizontal pin through the glans (Ampallang or \"crossbar\")",
"        </p>",
"       </td>",
"       <td>",
"        6 to 9 months or longer",
"       </td>",
"       <td>",
"        <p>",
"         Relatively uncommon",
"        </p>",
"        <p>",
"         May bleed until healing is complete",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rim of glans (Dydoe)",
"       </td>",
"       <td>",
"        3 to 4 months or longer",
"       </td>",
"       <td>",
"        Reportedly only worn by circumcised men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enters through the urethra and exits through the juncture of the glans and shaft or the dorsum of the penis (Prince Albert or reverse Prince Albert)",
"       </td>",
"       <td>",
"        1 to 2 months&nbsp; or longer",
"       </td>",
"       <td>",
"        <p>",
"         Popular piercing",
"        </p>",
"        <p>",
"         Has the most complications cited in the medical literature, but the total number of citations is few",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Juncture of the shaft and pubic mound (Pubic or \"rhinoceros horn\")",
"       </td>",
"       <td>",
"        3 to 4 months or longer",
"       </td>",
"       <td>",
"        Less painful than other types",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frenum/frenulum",
"       </td>",
"       <td>",
"        3 to 4 months or longer",
"       </td>",
"       <td>",
"        Easier to execute and less painful than other penis piercings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between testis and base of penis (Hafada)",
"       </td>",
"       <td>",
"        3 to 4 months or longer",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Foreskin (Oetang)",
"       </td>",
"       <td>",
"        2&nbsp;to&nbsp;3 months or longer",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between the scrotum and anus, behind the testes (Guiche)",
"       </td>",
"       <td>",
"        3 to 4 months or longer",
"       </td>",
"       <td>",
"        Sitting may be painful during healing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Outer labia",
"       </td>",
"       <td>",
"        4 to 10 weeks",
"       </td>",
"       <td>",
"        Often placed for appearance rather than sexual stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inner labia",
"       </td>",
"       <td>",
"        Short if post-piercing instructions are followed",
"       </td>",
"       <td>",
"        Piercing hole vanishes quickly after removal of ring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clitoris (horizontal placement)",
"       </td>",
"       <td>",
"        4 to 10 weeks",
"       </td>",
"       <td>",
"        <p>",
"         Most frequent choice for females",
"        </p>",
"        <p>",
"         Typically placed above clitoris for sexual stimulation (actual piercing of the clitoris is difficult and painful)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Between vagina and anus (Fourchette)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Requires scrupulous hygiene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nipple",
"       </td>",
"       <td>",
"        6 weeks to 6 months",
"       </td>",
"       <td>",
"        <p>",
"         Breastfeeding is not normally constrained if milk ducti remain intact; whether&nbsp;the jewelry is left intact during breastfeeding depends on the type of jewelry and the \"latch-on\" of the infant; any jewelry that poses a risk of aspiration in the infant should be removed",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    *",
"    <strong>",
"     These piercings should only be performed by experienced piercers.",
"    </strong>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <ol>",
"      <li>",
"       Stirn A. Body piercing: medical consequences and psychological motivations. Lancet 2003; 361:1205.",
"      </li>",
"      <li>",
"       Nelius T, Armstrong ML, Rinard K, et al. Genital piercings: diagnostic and therapeutic implications for urologists. Urology 2011; 78:998.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10141=[""].join("\n");
var outline_f9_57_10141=null;
var title_f9_57_10142="Bennett lipseal";
var content_f9_57_10142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lipseal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bennett Lipseal used for mouthpiece ventilator (Nellcor Puritan Bennett, Inc).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10142=[""].join("\n");
var outline_f9_57_10142=null;
var title_f9_57_10143="Dx biliary obstruction";
var content_f9_57_10143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation of suspected biliary obstruction after liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 500px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnostic algorithm for the evaluation of suspected biliary obstruction after liver transplantation.",
"    <div class=\"footnotes\">",
"     HA: hepatic artery; RUQ: right upper quadrant; US: ultrasound; MRCP: magnetic resonance cholangiopancreatography; ERC: endoscopic retrograde cholangiography; PTC: percutaneous transhepatic cholangiography.",
"     <br>",
"      * Abnormal liver enzymes include: aspartate aminotransferase; alanine aminotransferase; total bilirubin; alkaline phosphatase, and gamma glutamyltransferase.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres C&aacute;rdenas, MD, MMSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_57_10143=[""].join("\n");
var outline_f9_57_10143=null;
